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INTRODUCTION 
 
Health Care Associated Infection (HCAI), also referred to as 
“nosocomial” or “hospital” infection, is defined as:  
“An infection occurring in a patient during the process of care, in a health 
care facility, which was not present or incubating at the time of admission. An 
infection manifested >48 hours after admission is defined as hospital acquired. 
This includes infections acquired in the hospital but appearing after discharge 
and also occupational infections among the staffs.”  
HCAI is acknowledged as the most frequent adverse event in health care, 
but the global burden remains unknown because of the difficulty of gathering 
reliable data. This is mainly due to the complexity and lack of uniformity of 
diagnostic criteria and to the fact that surveillance systems for HCAI are 
virtually non-existent in most countries. 
Hospital acquired infections are a serious problem in patient care and 
adversely affect the mortality and morbidity. The affected areas are mainly the 
ICU and acute wards where the patients are critical and immune-compromised. 
Nosocomial infections complicate the primary disease process and create 
problems like septicemia and ARDS. They remain endemic in critical care 
wards and lead to epidemic outbreaks. 
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 Health Care Associated Infections (HCAI) are preventable errors. The 
improvement of the quality of the health care is a major concern for intensive 
care professionals because, the patients of the ICU are thought to be particularly 
at risk of errors due to complexity of the patients, interdependence of the 
practitioners, and dependence on team functioning, ensuring patients’ safety 
during their hospital stay which requires mechanisms to determine the incidence 
of adverse events. In the ICU, the accumulation of a number of immuno-
compromised patients and their nursing and invasive procedures provide a 
favorable environment to the growth and transmission of nosocomial infections. 
The use of a ventilator or a central venous catheter, and ICU acquired drug-
resistant infections were associated with a high risk of hospital mortality in ICU 
patients.     
 The potential impact on hospital mortality emphasizes the importance of 
preventive measures against ICU acquired infections; ICU acquired infection is 
common and often associated with microbiological isolates of resistant 
organisms. The potential effects on outcome emphasize the importance of 
specific measures for infection control in critically ill patients. Continued 
surveillance, along with sound infection control programs, not only lead to 
decreased health care associated infections but also better prioritization of 
resources and efforts to improving medical care. 
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AIMS & OBJECTIVES 
 To identify the prevalence and pattern of infections in critical care area.  
 To identify the predominant infecting organisms. 
 To determine the bacteriologic profile. 
 To see if there is any significant reduction in the incidence of hospital 
acquired infections by adoption of preventive measures. 
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REVIEW OF LITERATURE 
The word   NOSOCOMIAL infection is derived from Latin word 
nosocomium 1 hospital, Greek meaning nosokomeion, nosokomos one who tends 
the sick, from nosos disease + -komos2 ; akin to Greek kamnein to suffer, toil, 
Sanskrit śāmyati he tires3. 
 HISTORICAL MILESTONES 
One of the earliest records of hospital infections are perhaps those found 
in an Egyptian papyrus4 written around 3000 B.C. Needless to say, mere 
absence of documentation of bacterial infection does not exclude its prevalence 
prior to this time. 
Nearer home, in the Indian context, a similar account of hospital infection 
is available in the ancient Ayurvedic literature (Ca. 600 B.C.). Again the famous 
Hindu physician Charaka and surgeon Sushuruta5 (Ca. 400 B.C.) have also 
emphasized the need for prevention of infection in clinical practice. Elsewhere 
in the world too, there is ample evidence that hospital infections were prevalent 
and documented in ancient times viz: the records of Herodatus6 on the 
conditions that prevailed in Greek and Roman hospitals in the period 1000 to 
600 B.C., and the Hippocrates treatise (Ca 400 BC) testifying the existence of 
infections7. 
For several subsequent centuries that followed, it was generally believed 
that the disease was caused by the contagion8 and spread by wind and various 
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other types of air currents. It soon became recognized that certain medicaments 
were capable of either preventing or checking the progress of infection. Place in 
1721 used the term Antiseptics9 to describe these substances and, nearly 30 
years later, Pringle in 175010 conducted extensive trials with antiseptics while 
working with the British army in Flanders. 
In 1856 Louis Pasteur conclusively demonstrated that bacteria were 
responsible for fermentation of wine, which could be prevented by gentle 
heating whereby the micro-organisms were destroyed11. The existence of such 
micro-organisms in the atmosphere was proved by him in 1864. In his 
celebrated lecture to Acadimie de Medicine on April 30th, 187312, Louis 
Pasteur is quoted13 as having said: 
“If I had the honour of being a surgeon, not only would I use 
absolutely clean  instruments, but after cleaning my hands with 
the greatest care would only use sponges previously raised to a 
heat of 1300-1500 Fahrenheit. I would still have to fear germs 
suspended in the air, and surrounding the bed of the patient”. 
The now well known work of Semmelweiss (1861)14 on puerperal sepsis 
was largely disregarded at that time. He observed that puerperal sepsis was 
associated with medical staff and students who attended patients and also 
performed autopsies. Semmelweiss deduced that morbid matter present on their 
hands derived from cadavers15 or other patients was responsible for spread of 
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the disease. A drastic reduction in infection rates was achieved by the 
introduction of hand washing practices with chlorinated lime16. 
In 1969, Lister introduced his antiseptic theory17, following the extensive 
use of carbolic acid18 to pack wounds, especially of compound fractures, 
sterilize instruments and sutures, and to decontaminate his hands. He observed 
that these practices could greatly reduce the incidence of suppuration and 
gangrene, which quite commonly occurred otherwise. 
In 1883, Gustao Neubar introduced the use of masks and gowns in 
surgery19, and Halsted in 1890, introduced the use of rubber gloves20 in 
surgery. Steam sterilization21 was discovered by Von Bergman in 1896 and all 
these measures further increased the safety of surgery and contributed greatly in 
bringing down rates of infection by use of aseptic and antiseptic techniques. 
During the period, when many fundamental discoveries in bacteriology were 
being made, other principles of hospital infection control were also 
simultaneously established. 
BACKGROUND 
The ICU is highly specified and sophisticated area of a hospital which is 
specifically designed, staffed, located, furnished and equipped, dedicated to 
management of critically ill patients, injuries or complications22. It is a 
department with dedicated medical, nursing and allied staff. It operates with 
defined policies, protocols and procedures, having its own quality control, 
education, training and research programmes.23  
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Patients in Intensive Care Units (ICUs) have a higher risk of acquiring 
hospital associated infections than those in non-critical care areas. ICUs are 
sites of considerable broad spectrum antibiotic use, and antibiotic resistant 
pathogens are frequent. Bloodstream infections (BSIs), pneumonias, and 
Urinary Tract Infections (UTIs) are the most common hospital acquired 
infections and are most often associated with the use of invasive devices.24 
FREQUENCY OF INFECTION 
Every year, thousands of patients die of hospital acquired infections 
(HAI) in India. Death due to HAI is responsible for more mortality than any 
other forms of accidental death in the country. The irony is, about one–third of 
all such cases are preventable. 
"According to the report by the INICC in 2006, overall 1.4 million people 
worldwide are suffering from nosocomical infections and in India alone, the 
infection rate is at over 25 per cent,"25 HAI are mainly device associated 
infections. Devices are invasive procedures and thus they cause infection due to 
contamination of devices. Since patients in the ICU are likely to have multiple 
devices for treating or monitoring their care, it is not surprising that the most 
common nosocomial infections are pneumonia (endotracheal tubes), urinary 
tract infections (urinary catheters) and catheter related blood stream infections. 
Urinary catheter, ventilator associated, and catheter associated bloodstream 
infections are common complications of care provided in the ICU. Attributable 
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mortality for pneumonia occurring in the ICU population alone is between 5 – 
14%. 
Several studies 26,27,28,29 have shown that the utilisation of invasive 
devices such as venous and urinary catheter, ETT, intracranial pressure 
monitoring devices is a major risk factor for the development of nosocomial 
infections in ICU. Thus the incidences of such infections are expressed as 
number of infection/1000 device utilisation days. Early removal of such 
invasive devices will eliminate the risk of such device associated infections. 
However critical conditions of many ICU patients often require continued use 
of these catheters, tubes, and drains.   
Similarly, contamination during care of the devices also causes infection. 
Most common HAI is ventilator associated pneumonia (VAP). The incidence of 
VAP is 11 per 1,000 device days followed by catheter associated blood stream 
infection (BSI) which is 8 per 1000 device days and then by urinary tract 
infections.30 
  Data reveals that HAI increases the length of stay from 2 to 5 days and 
thereby increasing cost to patients. As per an estimate in Argentina, the increase 
in cost due to HAI is around $5000 and in India, it could be about Rs. 25,000 to 
100,000 depending on severity and hospital31. 
FACTORS INFLUENCING THE DEVELOPMENT OF NOSOCOMIAL 
INFECTIONS 
 
15 
 
 
THE MICROBIAL AGENT33 
The patient is exposed to a variety of micro-organisms during 
hospitalization. Contact between the patient and a micro-organism does not by 
itself necessarily result in the development of clinical disease, but other factors 
also influence the nature and frequency of nosocomial infections. The likelihood 
of exposure leading to infection depends partly on the characteristics of the 
micro-organisms, including resistance to antimicrobial agents, intrinsic 
virulence, and amount (inoculum) of infective material. Many different bacteria, 
viruses, fungi and parasites may cause nosocomial infections. Infections may be 
caused by a micro-organism acquired from another person in the hospital 
(cross-infection) or may be caused by the patient’s own flora (endogenous 
infection). Some organisms may be acquired from an inanimate object or 
substances recently contaminated from another human source (environmental 
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infection). Most infections acquired in hospital today are caused by micro-
organisms which are common in the general population, in whom they cause no 
or milder disease than among hospital patients (Staphylococcus aureus, 
coagulase-negative staphylococci, Enterococci, Enterobacteriaceae). 
PATIENT SUSCEPTIBILITY34 
Important patient factors influencing acquisition of infection include age, 
immune status, underlying disease, and diagnostic and therapeutic interventions. 
The extremes of life — infancy and old age — are associated with a decreased 
resistance to infection. Patients with chronic diseases such as malignant tumors, 
leukemia, diabetes mellitus, renal failure or the acquired immunodeficiency 
syndrome (AIDS) have an increased susceptibility to infections with 
opportunistic pathogens. Immunosuppressive drugs or irradiation may lower 
resistance to infection. Injuries to skin or mucous membranes bypass natural 
defense mechanisms. Malnutrition is also a risk. Many modern diagnostic and 
therapeutic procedures, such as biopsies, endoscopic examinations, 
catheterization, intubation/ventilation and suction and surgical procedures 
increase the risk of infection.  
ENVIRONMENTAL FACTORS35 
Health care settings are an environment where both infected persons and 
persons at increased risk of infection congregate. Patients with infections or 
carriers of pathogenic micro-organisms admitted to hospital are potential 
sources of infection for patients and staff. Patients who become infected in the 
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hospital are a further source of infection. Crowded conditions within the 
hospital, frequent transfers of patients from one unit to another, and 
concentration of patients highly susceptible to infection in one area (e.g. 
newborn infants, burn patients, and intensive care) all contribute to the 
development of nosocomial infections. Microbial flora may contaminate 
objects, devices, and materials which subsequently contact susceptible body 
sites of patients 
NOSOCOMIAL INFECTION SITES 
 
URINARY INFECTIONS 
Urinary infection is the most common nosocomial infection, 80% of 
infections are associated with the use of an indwelling bladder catheter36, 37, 38. 
Urinary infections are associated with less morbidity than other nosocomial 
infections, but can occasionally lead to bacteraemia and death. Infections are 
usually defined by microbiological criteria: positive quantitative urine culture 
(≥105 micro-organisms/ml, with a maximum of 2 isolated microbial species). 
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The bacteria responsible arise from the gut flora, either normal (Escherichia 
coli) or acquired in hospital (multi-resistant Klebsiella). 
NOSOCOMIAL PNEUMONIA 
Nosocomial pneumonia39 occurs in several different patient groups. The 
most important are patients on ventilators40 in intensive care units, where the 
rate of pneumonia is 3% per day. There is a high case fatality rate41 associated 
with ventilator associated pneumonia, although the attributable risk is difficult 
to determine because patient’s co morbidity is so high.  
The definition of pneumonia may be based on clinical and radiological 
criteria which are readily available but non-specific: recent and progressive 
radiological opacities of the pulmonary parenchyma, purulent sputum, and 
recent onset of fever. Diagnosis is more specific when quantitative 
microbiological samples are obtained using specialized protected bronchoscopy 
methods. Known risk factors42 for infection include the type and duration of 
ventilation, the quality of respiratory care, severity of the patient’s condition 
(organ failure), and previous use of antibiotics.  
Apart from ventilator associated pneumonia, patients with seizures or 
decreased level of consciousness are at risk for nosocomial infection, even if not 
intubated. Viral bronchiolitis (respiratory syncytial virus, RSV) is common in 
children’s units, and influenza and secondary bacterial pneumonia may occur in 
institutions for the elderly. With highly immune-compromised patients, 
Legionella spp. and Aspergillus pneumonia may occur.  
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NOSOCOMIAL BACTERAEMIA 
These infections represent a small proportion of nosocomial infections 
(approximately 5%) but case fatality rates43 are high — more than 50% for 
some micro-organisms. The incidence is increasing; particularly for certain 
organisms such as multi-resistant coagulase negative Staphylococcus and 
Candida spp. Infection may occur at the skin entry site of the intravascular 
device44, or in the subcutaneous path of the catheter (tunnel infection). 
Organisms colonizing the catheter within the vessel may produce bacteraemia 
without visible external infection. The resident or transient cutaneous flora is 
the source of infection. The main risk factors are the length of catheterization, 
level of asepsis at insertion, and continuing catheter care. 
 
 OTHER NOSOCOMIAL INFECTIONS 
These are the four most frequent and important nosocomial infections, 
but there are many other potential sites of infection. For example: 
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 Skin and soft tissue infections: open sores (ulcers, burns and bedsores) 
encourage bacterial colonization and may lead to systemic infection. 
 Gastroenteritis is the most common nosocomial infection in children, 
where rotavirus is a chief pathogen: Clostridium difficile is the major 
cause of nosocomial gastroenteritis in adults in developed countries. 
 Sinusitis and infections of the eye and conjunctiva. 
 Endometritis and other infections of the reproductive organs following 
childbirth. 
MICRO-ORGANISMS 
Many different pathogens may cause nosocomial infections. The 
infecting organisms vary among different patient populations, different health 
care settings, different facilities, and different countries. 
BACTERIA 
These are the most common nosocomial pathogens. A distinction may be 
made between: 
Commensal bacteria45 found in normal flora of healthy humans. These 
have a significant protective role by preventing colonization by pathogenic 
micro-organisms. Some commensal bacteria may cause infection if the natural 
host is compromised.  
Pathogenic bacteria46 have greater virulence, and cause infections (sporadic 
or epidemic) regardless of host status. For example: 
 Anaerobic gram-positive rods (e.g. Clostridium) cause gangrene. 
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 Gram-positive cocci - Staphylococcus aureus (cutaneous bacteria that 
colonize the skin and nose of both hospital staff and patients) cause a 
wide variety of lung, bone, heart and bloodstream infections and are 
frequently resistant to antibiotics; beta hemolytic streptococci are also 
important. 
 Gram-negative bacteria- Enterobacteriacae (e.g. Escherichia coli, 
Proteus, Klebsiella, Enterobacter, Serratia marcescens), may colonize 
sites when the host defenses are compromised (catheter insertion, bladder 
catheter, cannula insertion) and cause serious infections (surgical site, 
lung, bacteraemia, peritoneum infection). They may also be highly 
resistant. Gram-negative organisms such as Pseudomonas spp. are often 
isolated in water and damp areas. They may colonize the digestive tract 
of hospitalized patients. 
 Selected other bacteria are a unique risk in hospitals. For instance, 
Legionella species may cause pneumonia (sporadic or endemic) through 
inhalation of aerosols containing contaminated water (air conditioning, 
showers, and therapeutic aerosols). 
VIRUSES 
There is the possibility of nosocomial transmission of many viruses, 
including the hepatitis B and C viruses (transfusions, dialysis, injections, 
endoscopy), respiratory syncytial virus (RSV), rotavirus, and enteroviruses 
(transmitted by hand-to-mouth contact and via the faeco-oral route). Other 
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viruses such as cytomegalovirus, HIV, Ebola, influenza viruses, herpes simplex 
virus, and varicella-zoster virus, may also be transmitted. 
PARASITES AND FUNGI 
Some parasites (e.g. Giardia lamblia) are transmitted easily among adults 
or children. Many fungi and other parasites are opportunistic organisms and 
cause infections during extended antibiotic treatment and severe immune-
suppression (Candida albicans, Aspergillus spp., Cryptococcus neoformans, 
Cryptosporidium). These are a major cause of systemic infections among 
immune-compromised patients. Environmental contamination by airborne 
organisms such as Aspergillus spp. which originate in dust and soil is also a 
concern, especially during hospital construction. Sarcoptes scabies (scabies) is 
an ectoparasite which has repeatedly caused outbreaks in health care facilities 
RESERVOIRS AND TRANSMISSION 
Bacteria that cause nosocomial infections can be acquired in several 
ways: 
1. The permanent or transient flora of the patient (endogenous infection47)  
Bacteria present in the normal flora cause infection because of 
transmission to sites outside the natural habitat (urinary tract), damage to 
tissue (wound) or inappropriate antibiotic therapy that allows overgrowth 
(C. difficile, yeast spp.). For example, gram-negative bacteria in the 
digestive tract frequently cause surgical site infections after abdominal 
surgery or urinary tract infection in catheterized patients. 
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2. Flora from another patient or member of staff (exogenous cross-
infection48) 
Bacteria are transmitted between patients: 
a) Through direct contact between patients (hands, saliva droplets or 
other body fluids) 
b) In the air (droplets or dust contaminated by a patient’s bacteria) 
c) Via staff contaminated through patient care (hands, clothes, nose 
and throat) who become transient or permanent carriers, 
subsequently transmitting bacteria to other patients by direct 
contact during care 
d)  Via objects contaminated by the patient (including equipment), the 
staff’s hands, visitors or other environmental sources (e.g. water, 
other fluids, food) 
3. Flora from the health care environment49 (endemic or epidemic exogenous 
environmental infections) 
        Several types of micro-organisms survive well in the hospital environment: 
• In water, damp areas, and occasionally in sterile products or 
disinfectants (Pseudomonas, Acinetobacter, Mycobacterium) 
• In items such as linen, equipment and supplies used in care; 
appropriate housekeeping normally limits the risk of bacteria 
surviving 
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• As most micro-organisms require humid or hot conditions and 
nutrients to survive 
• In food 
• In fine dust and droplet nuclei generated by coughing or speaking 
(bacteria smaller than 10 µm in diameter remain in the air for several 
hours and can be inhaled in the same way as fine dust) 
SOURCES OF CROSS INFECTION (50, 51, 52) IN THE ICU 
o Hands of staff and attendants (via two bowl hand washing and 
communal towels or no hand washing) 
o Assisted ventilation equipment 
o Suction and drainage bottles 
o I.V. lines – central and peripheral 
o Urinary catheters 
o Wounds and wound dressings 
o Disinfectant containers 
o Dressing trolleys (on which disinfectants jars/bottles are stored) 
SURVEILLANCE 
Surveillance53 is the systematic ongoing collection, collation and analysis 
of data with timely dissemination of information to those who require it in order 
to take action. The actions usually relate to improvements in prevention or 
control of the condition. Health care associated infections are an important and 
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growing hospital and public health concern. Both the prevalence of antibiotic 
resistant organisms and of a vulnerable, immuno-compromised population is 
increasing in hospitals and long term care homes. There is conclusive evidence 
to show that the establishment of a surveillance system for HAIs is associated 
with reductions in infection rates. Surveillance is also useful in monitoring the 
effectiveness of preventive and infection control programs. 
There are several established components to an active & effective 
surveillance system: 
1. PLANNING 
Because it is not feasible to monitor all types of infections at all times, 
choosing which infections will be surveyed is based upon an initial assessment 
that will establish the priorities for the surveillance system54. An initial 
assessment will include: 
• The types of patients/residents that are served by the health care setting 
• The key medical interventions and procedures that are provided in the 
health care setting 
• The frequency of particular types of infections within a particular health 
care setting 
• The impact of the infection (including per cent case fatality and excess 
costs associated with the infection)  
• The preventability of the infection 
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Surveillance for some types of infections and syndromes, such as Febrile 
Respiratory Illness (FRI) and Gastrointestinal Illness (GI) are currently part of 
routine practice in all health care settings. 
2. DATA COLLECTION 
Collection of infection data for surveillance purposes55 must be done 
using validated, published definitions for HAIs. In order to generate valid HAI 
rates, information must be collected on those who develop a HAI and those who 
do not develop infection. Electronic screening56 of patient records is an 
emerging tool for identification of potential HAIs. These computerized systems 
of case finding will reduce the time spent by infection control professionals in 
case finding.  
3. DATA ANALYSIS 
It is recommended that incidence density rates be calculated57 i.e., the 
measurement of new cases of infection (incidence) based on the time at risk in 
the patient/resident population, e.g., length of stay in a hospital. It may be useful 
in hospitals to stratify rates of surgical site infections by standardized risk 
scores58 in order to compare the rates to other hospitals. An electronic 
spreadsheet/database and/or statistical analysis program should be used in 
hospitals and long-term care homes to store data and calculate HAI rates, to 
maximize infection prevention and control resources and reduce the potential 
for errors associated with manual calculations. 
4. INTERPRETATION OF DATA 
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Surveillance data requires interpretation to identify areas where 
improvements to infection prevention and control practices can be implemented 
to lower the risk of HAI. This investigation is particularly essential where major 
deviations from the baseline HAI rate may indicate the presence of an 
outbreak59. Analysis and interpretation of infection data may be done with the 
facility’s Infection Prevention and Control Committee or other advisory body to 
the Infection Control Team. HAI rates may be compared to both the facility’s 
own previous HAI rates and benchmarks, or to external standards or 
benchmarks set by other health care settings60.  
5. COMMUNICATION OF RESULTS 
Communication of surveillance data should take place on an ongoing, 
systematic basis and be targeted61 to those with the ability to change infection 
prevention and control practice. Communication may be targeted to: 
• A health care setting’s Infection Prevention and Control Committee, 
which provides an aggregate picture of all infections of interest in the 
hospital 
• A particular patient/resident care area or specialty care area, focused on 
the risk of specific types of infections that are of importance to these 
groups 
• Patient/resident care staff following the identification of an emerging risk 
of infection, to remind or to notify the required precautions in infection 
prevention and control 
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6. EVALUATION 
Periodic review62 of the surveillance system should be part of regular 
Infection Prevention and Control Committee meetings in hospitals and long-
term care homes and should include an assessment of the outcomes to which the 
surveillance system contributes. Evaluation should include how information 
produced by a surveillance system is used to reduce the risk of health care 
associated infection63. Outcome evaluation should take place at least annually 
and a realignment of surveillance objectives undertaken when indicated. The 
steps provided in this best practices guide will assist infection prevention and 
control professionals to develop and implement their surveillance programs in a 
manner that will permit comparisons with their peers and allow them to quickly 
detect early increases in health care associated infections that may indicate the 
presence of an outbreak. 
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DESIRED CHARACTERISTICS OF A NOSOCOMIAL INFECTION 
SURVEILLANCE SYSTEM64, 65, 66* 
1. CHARACTERISTICS OF THE SYSTEM 
• Timeliness, simplicity and flexibility 
• Acceptability and reasonable cost 
• Representativeness (or exhaustiveness) 
2. QUALITY OF THE DATA PROVIDED 
• Sensitivity and specificity 
• Predictive value (positive and negative) 
• Usefulness, in relation to the goals of the surveillance (quality indicators) 
* Adapted from Thacker SB, 1988 (4).  
KEY POINTS IN THE PROCESS OF SURVEILLANCE FOR 
NOSOCOMIAL INFECTION RATES 
• Active surveillance (prevalence and incidence studies) 
• Targeted surveillance (site, unit, priority-oriented) 
• Appropriately trained investigators 
• Standardized methodology 
• Risk adjusted rates for comparisons 
An effective surveillance system must identify priorities for preventive 
interventions and improvement in quality of care67. By providing quality 
indicators, surveillance enables the infection control programme, in 
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collaboration with patient care units, to improve practice, and to define and 
monitor new prevention policies. The final aim of surveillance is to decrease 
nosocomial infections and reduce costs. 
Surveillance is a continuous process which needs to evaluate the impact 
of interventions to validate the prevention strategy, and determine if initial 
objectives are attained. 
PREVENTIVE MEASURES 
ENVIRONMENTAL MANAGEMENT PRACTICES 
A clean environment plays an important role in the prevention of hospital 
associated infections (HAI) 68. Many factors, including the design of patient care 
areas, operating rooms, air quality, water supply and the laundry can 
significantly influence the transmission of HAI. 
CLEANING OF THE HOSPITAL ENVIRONMENT 
Routine cleaning is important to ensure a clean and dust free hospital 
environment69. There are usually many micro-organisms present in “visible 
dirt”, and routine cleaning helps to eliminate this dirt. Administrative and office 
areas with no patient contact require normal domestic cleaning. Most patient 
care areas should be cleaned by wet mopping70. Dry sweeping is not 
recommended. The use of a neutral detergent solution improves the quality of 
cleaning. Hot water (80°C) is a useful and effective environmental cleaner. 
Bacteriological testing of the environment is not recommended unless seeking a 
potential source of an outbreak. 
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Any areas visibly contaminated with blood or body fluids should be 
cleaned immediately with detergent and water. Isolation rooms and other areas 
that have patients with known transmissible infectious diseases should be 
cleaned with a detergent disinfectant solution at least daily. All horizontal 
surfaces and all toilet areas should be cleaned daily. 
ENVIRONMENTAL CLEANING71 
DAILY 
• Cleaning must be done daily with the hospital approved cleaner. All 
surfaces must be wiped with a damp cloth to remove dust and dirt 
• Cleaner/disinfectants should be identified by the Intensive care team and 
used as indicated. High level disinfectants (HLD) are not used for 
environmental cleaning. 
• Cleaner/disinfectants should be kept closed when not in use. 
TERMINAL 
• When patients are discharged from the unit, a thorough cleaning of the 
bed and bedside equipment must be completed before admitting new 
patients. 
SCHEDULED 
• A total cleaning of all areas, including the store clean and soiled storage 
areas should be done at least every 1-2 weeks. 
• Separate mops and cleaning utensils should be used for cleaning of the 
unit. 
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• Cleaning equipment should be wiped & properly stored when not in use. 
UNIT DESIGN72 
Unit design should consider the following to enhance infection control 
strategies. 
SPACE 
BEDS 
The beds should be 2.5 - 3 meters (7-9 feet) apart, to allow free 
movement of staff and equipment, reducing risk of cross contamination. Ideally, 
a sharps container should be within easy access of each bed. 
PARTITIONS 
Privacy partitions should be of material that is easily cleaned and should 
be cleaned weekly and any time that it becomes soiled or contaminated. If 
curtains are used, they should be changed weekly and between patients. 
MEDICATION PREPARATION 
Medication preparation areas should be separate from patient care areas 
and should be maintained as a clean area. 
CLEAN STORAGE 
An area should be identified and maintained for clean storage and should 
be separate from care and waste disposal areas. 
SOILED AND WASTE STORAGE 
An area should be identified for storing collected bedside waste and 
should be maintained separate from direct care and clean medication areas. 
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Ideally, this area should have a clinical sink for the disposal of blood and body 
fluid waste. The area should include storage of filled sharps containers until 
these containers can be removed. 
TOILETS 
May be located outside the ICU. 
SINKS AND WATERLESS HAND RUB DISPENSERS 
Sinks should be placed near the ICU entrance and at key points, within 
the unit in order to provide ease of access to the care givers. If this is not 
feasible, waterless hand rub dispensers73 should be available at the ICU entrance 
and at each bedside.  
VENTILATION 
TYPE 
The source of clean air should be determined including central or through 
the wall air conditioning units. System should be evaluated for proper 
functioning and preventive maintenance. 
The air conditioning filters should be cleaned periodically and fans that 
can spread airborne pathogens should be avoided in high risk areas. High risk 
areas such as operating rooms, critical care units and transplant units require 
special ventilation systems. Filtration systems (air handling units) designed to 
provide clean air should have high efficiency particulate air (HEPA) filters74 in 
high risk areas. Unidirectional laminar airflow systems should be available in 
appropriate areas in the hospital construction.  
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WINDOWS 
Windows should remain closed in order to control all airborne risks. 
VISITORS 
Design of the unit should permit staff to assess visitors for communicable 
disease (e.g. rash, respiratory infection) before permitted to enter unit. They 
should be instructed in washing their hands if assisting the patient. 
WATER 
Drinking water should be safe75 for oral ingestion. National norms and 
international recommendations define appropriate criteria for clean drinking 
water. Even water that conforms to accepted criteria may carry potentially 
pathogenic micro-organisms. Organisms present in tap water have frequently 
been implicated in nosocomial infections. These micro-organisms have caused 
infection of wounds (burns, surgical wounds), respiratory tract, and other sites 
(semi critical equipment such as endoscopes rinsed with tap water after they 
have been disinfected). Legionella spp. lives in hot water networks where the 
temperature promotes their development within protozoan phagosomes; tap 
aerators facilitate proliferation of these and other micro-organisms, such as 
Stenotrophomonas maltophilia.  
FOOD76 
Quality and quantity of food are key factors for patient convalescence. 
Ensuring safe food is an important service delivery in health care. 
 Maintain a clean work area. 
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  Maintain scrupulous personal hygiene among food handlers, especially 
hand washing, as hands are the main route of contamination.  
 Staff should change work clothes at least once a day, and keep hair 
covered. 
 Avoid handling food in the presence of an infectious disease (cold, 
influenza, diarrhoea, vomiting, throat and skin infections), and report all 
infections. 
 Use appropriate cooking techniques and follow recommendations to 
prevent growth of micro-organisms in food. 
  Food handlers should receive continuing instruction in safe practices. 
 Separate raw and cooked food to avoid cross contamination. 
 The catering system environment must be washed often and regularly 
with tap water and appropriate detergents (and/or disinfectants). 
LAUNDRY 
General instructions 
LINEN77 
The basic principles of linen management are as follows: 
 Place used linen in appropriate bags at the point of generation. 
 Contain linen soiled with body substances or other fluids within suitable 
impermeable bags and close the bags securely for transportation to avoid 
any spills or drips of blood, body fluids, secretions or excretions. 
 Do not rinse or sort linen in patient care areas (sort in appropriate areas). 
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 Separate clean from soiled linen and transport/store separately. 
 Wash used linen (sheets, cotton blankets) in hot water (70°C to 80°C) and 
detergent, rinse and dry preferably in a dryer or in the sun. (Heavy duty 
washers/dryers are recommended for the hospital laundry.)  
BEDDING 
 Mattresses and pillows with plastic covers should be wiped over with a 
neutral detergent. 
 Mattresses without plastic covers should be steam cleaned if they have 
been contaminated with body fluids. If this is not possible, 
contaminations should be removed by manual washing, ensuring 
adequate personnel and environmental protection. 
 Wash pillows either by using the standard laundering procedure or dry 
clean if contaminated with body fluids. 
WASTE MANAGEMENT 
Hospital waste is a potential reservoir of pathogenic micro-organisms and 
requires appropriate, safe and reliable handling. The main risk associated with 
infection is sharps contaminated with blood78. There should be a person or 
persons responsible for the organization and management of waste collection, 
handling, storage and disposal. Waste management should be conducted in 
coordination with the infection control team. Steps79 in the management of 
hospital waste include: 
 Generation. 
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 Segregation/separation. 
 Collection. 
 Transportation. 
 Storage. 
 Treatment. 
 Final disposal. 
METHODS OF DISPOSAL 
SHARPS 
 Autoclave, shred and land fill or microwave, shred and land fill or treat 
by plasma pyrolysis of puncture proof containers storing discarded 
sharps. 
 Deep burial in a secure area. Burial should be 2 to 3 meters deep and at 
least 1.5 meters above the groundwater table. 
Waste requiring incineration: 
 Anatomical parts and animal carcasses. 
 Cytotoxic drugs (residues or outdated). 
 Toxic laboratory chemicals other than mercury. 
Waste that may be incinerated: 
 Patient contaminated non-plastics and non-chlorinated plastics. 
Waste that should not be incinerated: 
 Chlorinated plastics. 
 Volatile toxic wastes such as mercury. 
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 Plastics, non-plastics contaminated with blood, body fluids, secretions. 
and excretions and infectious laboratory wastes. 
 Radioactive waste (should be dealt with according to national laws). 
PERSONAL HYGIENE 
All staff must maintain good personal hygiene. Nails must be clean and 
kept short. Hair must be worn short or pinned up. Beard and moustaches must 
be kept trimmed short and clean. 
HAND WASHING 
Appropriate hand washing can minimize micro-organisms acquired on 
the hands by contact with body fluids and contaminated surfaces. Hand washing 
breaks the chain of infection transmission and reduces person-to-person 
transmission80, 81. 
Hand washing is the simplest and most cost effective way82 of preventing 
the transmission of infection and thus reducing the incidence of health care 
associated infections. 
All health care personnel and family care givers of patients must practise 
effective hand washing. Patients and primary care givers need to be instructed83 
in proper techniques and situations for hand washing. 
TYPES OF HAND WASHING 
HAND WASHING 
Hand washing is usually limited to hands & wrists. The hands are washed 
for a minimum of 10 – 15 seconds with soap (plain or antimicrobial) & water. 
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HAND ANTISEPSIS/DECONTAMINATION87, 88 
Hand antisepsis removes or destroys transient micro-organisms and 
confers a prolonged effect. It may be carried out in one of the following two 
ways: 
 Wash hands and forearms with antimicrobial soap and water, for 15-30 
seconds (following manufacturer’s instructions).  
 Decontaminate hands with a waterless, alcohol based hand gel or hand 
rub for 15-30 seconds. This is appropriate for hands that are not soiled 
with protein matter or fat. 
Immersion of hands in bowls of antiseptics is not recommended. 
SURGICAL HAND ANTISEPSIS 
Surgical hand antisepsis removes or destroys transient micro-organisms 
and confers a prolonged effect.  
 The hands and forearms are washed thoroughly with an antiseptic soap 
for a minimum of 2-3 minutes.  
 The hands are dried using a sterile towel. 
Surgical hand antisepsis is required before performing invasive procedures 
MATERIALS USED FOR HAND WASHING/HAND ANTISEPSIS84 
1. Soap: Plain or antimicrobial soap depending on the procedure. 
2. Plain soap: Used for routine hand washing, available in bar, powder or                              
liquid form. 
3. Specific antiseptics recommended for hand antisepsis: 
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• 2%-4% chlorhexidine 
• 5%-7.5% povidone iodine 
• 1% triclosan 
• 70% alcoholic hand rubs 
Waterless, alcohol based hand rubs85, 90, 91 with antiseptic and emollient gel and 
alcohol swabs, which can be applied to clean hands. 
FACILITIES FOR DRYING HANDS 
Disposable towels, reusable single use towels or roller towels, which are 
suitably maintained, should be available. If there is no clean dry towel, it is best 
to air dry hands86. 
CLOTHING 
WORKING CLOTHES74 
Staff can normally wear a personal uniform or street clothes covered by a 
white coat. In special areas such as intensive care units, uniform trousers and a 
short sleeved gown are required for men and women. The working outfit must 
be made of a material easy to wash and decontaminate. If possible, a clean outfit 
should be worn each day.  
SHOES74 
In aseptic units and in operating rooms, staff must wear dedicated shoes, 
which must be easy to clean. 
CAPS74 
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In aseptic units, operating rooms, or performing selected invasive 
procedures, staff must wear caps or hoods which completely cover the hair. 
MASKS 74 
Masks of cotton wool, gauze, or paper are ineffective. Paper masks with 
synthetic material for filtration are an effective barrier against micro-organisms. 
Masks are used in various situations; mask requirements differ for different 
purposes. 
GLOVES74 
 Hands must be washed when gloves are removed or changed. 
 Disposable gloves should not be reused. 
 Latex or polyvinyl chloride is the materials mostly used for gloves.  
 Gloves should be selected according to need (e.g., sterile for procedures 
using aseptic technique such as insertion of central venous catheter and 
non-sterile for procedures such as emptying urinary drainage bags, 
insertion of peripheral IV catheters, contact with contaminated surfaces or 
equipment). 
 Change gloves and decontaminate hands, as above: 
• Between contacts with different patients. 
• After handling respiratory secretions or objects contaminated with 
secretions from one patient. 
• Before contact with another patient, object, or environmental 
surface. 
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• Between contacts with a contaminated body site and the respiratory 
tract of, or respiratory device on, the same patient. 
CARE OF HEALTH CARE WORKERS 
Health care workers (HCW) are at risk of acquiring infection through 
occupational exposure74, 92. Hospital employees can also transmit infections to 
patients and other employees. Employees’ health should be reviewed at 
recruitment, including immunization history and previous exposures to 
communicable diseases (e.g. tuberculosis) and immune status. Some previous 
infections such as varicella-zoster virus may be assessed by serological tests. 
Immunization recommended for staff includes: hepatitis A and B, influenza, 
measles, mumps, rubella, tetanus, and diphtheria. Immunization against 
varicella, rabies may be considered in specific cases. The Mantoux skin test will 
document a previous tuberculosis (TB) exposure.  
EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
The risk of a health care worker acquiring HIV after a needle stick or 
other “sharps” injury is less than 0.5%. Risk reduction must be undertaken for 
all blood borne pathogens, including adherence to standard precautions93,94 
using personal protective equipment and appropriate use of safety devices and a 
needle disposal system to limit sharps exposure. Training for health care 
workers in safe sharps practice should be ongoing95. Information on preventive 
measures must be provided to all staff with potential exposure to blood and 
blood products96. Policies which are in keeping with the local and national 
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guidelines must include screening of patients, disposal of sharps and wastes, 
protective clothing, managing inoculation accidents, sterilization and 
disinfection. Post exposure prophylaxis97 should be started as per local or 
national guidelines. 
EXPOSURE TO HEPATITIS B VIRUS98 
 Following standard precautions is important, but immunization99 is the 
best way of preventing transmission to health care staff. All HCWs at risk must 
be vaccinated. Staff infected with blood borne pathogens may transmit these 
infections to patients and require careful evaluation with respect to their duties. 
This status should not be used as cause for discrimination. 
EXPOSURE TO HEPATITIS C VIRUS 
The route of infection is mainly parenteral. Sexual transmission does 
occur but is far less frequent. No post exposure therapy is available100 for 
hepatitis C, but seroconversion (if any) must be documented. As for hepatitis B 
viral infection, the source person must be tested for HCV infection. For any 
occupational exposure to blood borne pathogens, counselling and appropriate 
clinical and serological follow-up must be provided. 
TUBERCULOSIS 
Health care workers have varying risks for exposure to tuberculosis (TB). 
Health care workers at the greatest risk of exposure94 are those working in TB 
risk areas such as medical wards, chest clinics, bronchoscopy units, radiology 
units, TB laboratories, HIV wards and autopsy rooms. If a staff member has 
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been exposed to TB, they should report to the Infection Control Practitioner or 
the Staff Health Nurse depending on the hospital protocol for health care worker 
exposures. 
SHARP INJURIES 
Needle stick injuries are the most common of sharps injuries101, although 
other contaminated sharp instruments may also cause injuries. All health care 
workers with potential exposure should be vaccinated. For other personnel, the 
risk of hepatitis B, hepatitis C and HIV infection should be assessed and 
appropriate immunization or chemoprophylactic steps taken. Immediate 
treatment of such injuries should encourage washing thoroughly with running 
water and an antiseptic solution. An incident reporting system should be in 
place102. It should not be seen as punitive; active support by managers should 
encourage prompt and accurate reporting. 
SAFE INJECTION PRACTICES103 
To prevent transmission of infections between patients with injections: 
 Eliminate unnecessary injections 
 Use sterile needle and syringe 
 Use disposable needle and syringes, if possible 
 Prevent contamination of medications 
 Follow safe sharps disposal practices 
PATIENT CARE EQUIPMENT 
Reprocessing & patient care practices for specialized equipment in the ICU72. 
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EQUIPMENT & PATIENT 
CARE ARTICLES 
REPROCESSING METHOD 
1. Ventilatory circuits 
 
• Disposable tubing does not routinely need to be changed for 
a single patient unless it becomes visibly contaminated, 
malfunctions or within 3-4 days. 
• Multiple use tubing must be heat disinfected for at least 76°C 
for 30 minutes or sterilized (see manufacturer’s guidelines). 
• The use of non-disinfected tubing between patients increases 
the risk of chest infection due to gram-negative bacilli, e.g. 
Pseudomonas aeruginosa. 
• If properly maintained, a ventilated patient may use the same 
circuit for 3-4 days before reprocessing becomes necessary. 
• When cost-effective and unless medically contraindicated, 
use a heat-moisture exchanger (HME) to prevent pneumonia in 
a patient receiving mechanically assisted ventilation. Change 
the HME when it malfunctions mechanically or becomes 
visibly soiled. 
• Do not routinely change a HME more frequently than every 
48 hours. Install filters, e.g. heat-moisture exchangers with 
filters (HMEF) on the expiratory and inspiratory ends of the 
ventilator to prevent contamination. 
2. Endotracheal suction 
catheters 
• Closed suction catheters that incorporate a protective sleeve 
do not need to be changed every 24 hours. Studies have 
demonstrated that these can safely be used on the same patient 
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EQUIPMENT & PATIENT 
CARE ARTICLES 
REPROCESSING METHOD 
until the device is contaminated or malfunctions. 
• More often, disposable suction catheters are used for 
respiratory tract suctioning. This device should be discarded 
after each use or may be used maximum for up to 6 hours on 
the same patient. 
• The water used for flushing the catheter after each suction 
must be sterile and changed every time.  
3. Endotracheal tubes • These may be recycled after thorough cleaning and 
autoclaving. 
•   Disposable endotracheal tubes are better.  
4. Ambu-bags • Ambu-bags are extremely difficult to disinfect and become 
contaminated very quickly. 
• Heat is the most reliable method of disinfection; 2% 
glutaraldehyde is a less acceptable method. 
• The bags must be rinsed thoroughly in sterile water after 
immersion in glutaraldehyde. This will reduce the risk of 
chemical irritation, which can itself precipitate respiratory 
infection. 
5. Oxygen delivery masks These can be disposable or reusable; 
• Wash thoroughly. 
• Soak in alcohol for 10 minutes or soak in chlorine (500 ppm), 
rinse, dry and store. 
6. Suction & drainage bottles These are usually disposable, with a self-sealing inner 
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EQUIPMENT & PATIENT 
CARE ARTICLES 
REPROCESSING METHOD 
container held in a clear plastic outer container. 
Non-disposable bottles: 
• Before buying a system, ensure that the outer container can 
be heat disinfected or autoclaved. 
• Must be changed every 24 hours (or sooner if full). 
• The contents may be emptied down in the toilet. 
• Must be rinsed and autoclaved. 
• If sterilizing facilities are not available, wash thoroughly, dry 
and perform high level disinfection. 
• Recyclable connector tubing should be cleaned thoroughly 
and sterilized. The system must be closed and risk to staff from 
body fluids should be minimal. 
 
7. Resuscitaires 
• Disconnect all connections. 
• Wash thoroughly with a soft brush and autoclave.\ 
PROCEDURES REQUIRING ASEPTIC TECHNIQUE 
INTRAVASCULAR DEVICE104,105,106 
INSERTION 
a) Clean injection ports with 70% alcohol or an iodophor before accessing 
the system. Cap all stopcocks when not in use. 
48 
 
b) Use aseptic technique including a cap, mask, sterile gown, sterile gloves, 
and a large sterile sheet for the insertion of central venous catheters 
(including PICCs) or guide wire exchange. 
c) After insertion, the area surrounding the catheter (introducer) will be 
cleansed with povidone iodine or chlorhexidine.  
d) Apply a sterile transparent adhesive dressing to cover the insertion site. 
e) Note down the date and time of insertion of the catheter. 
CARE AND MAINTENANCE 
All insertion sites will be evaluated daily (SOS) for the continued need 
for the device, signs/symptoms of infection, and the response to evidence of 
infection. Such evaluation will be documented in the patient chart. Dressings 
will be changed regularly. 
DURATION OF THE IV DEVICES 
1. CENTRAL CANNULA: 
a) All central cannulas shall be removed when no longer medically indicated 
or if they are strongly suspected of causing  sepsis.   
b) On the 7th consecutive day (and intervals thereafter) of an individual 
catheter via the same access, the  physician shall evaluate the insertion 
site and catheter and assess the continued need for the same, and 
document in the notes of the patient’s chart that the catheter is still 
medically indicated and the absence or presence of signs of sepsis.  
c) Pulmonary artery catheters must be removed or changed after 5 days.  
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2. PERIPHERAL CANNULA: 
a) Peripheral  IV access devices should be replaced every 72 hours. 
REMOVAL OF IV DEVICES 
a) Guide wire assisted catheter exchange may be used to replace a 
malfunctioning catheter or to convert an existing catheter if there is no 
evidence of infection at the catheter site. Attire and antiseptic technique 
should parallel that of insertion. 
b) If catheter related sepsis is suspected, but there is no evidence of local 
catheter related infection (e.g., purulent drainage, erythema, tenderness) 
the catheter may be changed over a guide wire.  
c) Do not use guide wire assisted catheter exchange whenever catheter 
related infection is documented. If the patient requires continued vascular 
access, remove the implicated catheter and replace it with another 
catheter at different insertion site. 
URINARY CATHETER: 107,108,109 
 Avoiding urethral catheterization unless there is a compelling indication 
limiting the duration of drainage, if catheterization is necessary. 
 Maintaining appropriate aseptic practice during urinary catheter insertion 
and other invasive urological procedures (e.g. cystoscopy, 
urodynamictesting, cystography). 
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 Hygienic hand wash or rub prior to insertion and following catheter or 
drainage bag manipulation. 
 Sterile gloves for insertion. 
 Perineal cleaning with an antiseptic solution prior to insertion. 
 Non-traumatic urethral insertion using an appropriate lubricant. 
 Maintaining a closed drainage system. 
Other practices which are recommended, but not proven to decrease 
infection include: 
 Maintaining good patient hydration. 
 Appropriate perineal hygiene for patients with catheters. 
 Appropriate staff training in catheter insertion and care. 
 Maintaining unobstructed drainage of the bladder to the collection bag, 
with the bag below the level of the bladder. 
 Generally, the smallest diameter catheter should be used. Catheter 
material (latex, silicone) does not influence infection rates. 
 For patients with a neurogenic bladder: 
 Avoid an indwelling catheter if possible. 
 If assisted bladder drainage is necessary, clean intermittent urinary 
catheterization should be used. 
RESPIRATORY CARE 
 If there is no medical contraindication, elevate the head of the bed of a 
patient at high risk for aspiration pneumonia e.g., a person receiving 
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mechanically assisted ventilation and/or who has an enteral tube in place, at 
an angle of 30-45 degrees. 
 Periodically drain and discard any condensate that collects in the tubing of a 
mechanical ventilator, taking precautions not to allow condensate to drain 
toward the patient.  
 If available, use an endotracheal tube with a dorsal lumen above the 
endotracheal cuff to allow drainage (by continuous suctioning) of tracheal 
secretions that accumulate in the patient's subglottic area. 
 Use sucralfate, H2-blockers, and/or antacids interchangeably for stress 
bleeding prophylaxis in a patient receiving mechanically assisted ventilation 
(H2-blockers alone decrease gastric acidity and increase gastric colonization 
and increases the susceptibility to respiratory infections). 
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MATERIALS AND METHODS 
STUDY DESIGN 
 Retrospective and Prospective Prevalence study 
STUDY CENTRE 
 Intensive Medical Care Unit 
 Government General Hospital, Chennai 
SELECTION OF PATIENTS 
1. INCLUSION CRITERIA 
 Patients with negative baseline cultures at the time of admission. 
 Health care professional who are not incubating any infection at the time 
of study. 
 Inanimate objects present in the intensive care units. 
2. EXCLUSION CRITERIA 
 All infected and septicemic patients at the time of admission are excluded 
from the study 
3. SAMPLE SIZE 
 Cultures from the environment, health care providers are taken weekly 
from critical care area. 
 Cultures are taken from patients in critical care area who fulfill the 
inclusion criteria with sample size of 200 
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MATERIALS AND METHODS 
Phase I: 
 Analysis of case sheets 
Phase II: 
 Uricol bottle 
 Tracheal aspirate sample containers 
 Blood culture bottle 
 Ames swabs 
 Culture media 
Phase III: 
 Uricol bottle 
 Tracheal aspirate sample containers 
 Blood culture bottle 
 Ames swabs 
 Culture media 
 Aprons, caps, masks, slippers  
 Running water and soap 
 Antiseptic lotion 
METHODOLOGY  
We started the study with Phase I  and we retrospectively analysed  the 
bateriologic  profile in the past three months in order to know about the pattern 
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of organisms prevalent before the study .The study was then further spread over 
two phases of three months each, Phase II and Phase III. In the Phase II of our 
study i.e., during the first three months, the regular ward routine were not 
disturbed and no new specialized preventive measure was introduced. The 
nursing staff continued to attend to their patients as per routine. Ward 
disinfection routine continued as before and waste disposal was carried out as 
per the standard policy of the hospital. Bacterial flora of ICU was monitored by 
weekly cultures from wall, floor, and other patient contact items like bed, 
oxygen giving masks, nasal catheters and antiseptic in use lotions (table below). 
 
ICU ENVIRONMENT PATIENT STAFF 
Wall Urine if catheterized Swabs from palms 
Floor Blood samples Nail bed 
Air settle plates Tracheal swabs  
Beds If necessary:  
Ventilator tubing Suction catheter tip with aspirate  
Oxygen masks CVP cath tip  
Nasal catheters Intra cath tip  
Antiseptic inuse lotion Wound swabs  
Linen/dress Tracheal swabs  
 
Patient surveillance for nosocomial infections was done as excluding 
patients with sepsis by taking cultures from urine specimens if catheterised, 
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tracheal aspirates, blood and CVP catheter tip and intracath tips were cultured 
whenever changed. All the swabs were taken before any antiseptic procedure 
was carried out. 
All the ICU staffs were educated about the aim of the study and details of 
the protocol to ensure their participation from time to time.  The entry of the 
visitors was restricted to only one at a time for maximum five minutes during 
the visiting hours. Hand washing facilities were improved by providing running 
warm water and liquid soft soap near the central nursing station. The staff were 
explained the importance of repeated hand washing immediately before and 
after every episode of patient contact or nursing activity in prevention of cross 
infection. They were instructed to wash hands immediately before and after 
handling each patient in specific manner as advocated to prevent contact of 
washed areas with unwashed areas of hands. In the Phase III study, the bacterial 
monitoring of the ICU environment, surveillance of the staff and the patients 
was continued as in Phase II. 
First category consisted of all the culture specimens taken from the 
different patient sites to demonstrate their infected status as they were regarded 
as potential source capable of harbouring and spreading the nosocomial 
infections. Second category consisted of ICU environment wherein all the 
culture specimens from ICU wall, floor, bed, linen and other patient contact 
equipments were included. This information was felt essential to determine the 
pattern of overall bacterial flora existing in ward, its potential in harbouring the 
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infection and also the efficacy of various existing infection control methods 
being followed. 
The results obtained in both phases for each category were finally 
compared as percentage and further statistically analysed for any significant 
change, by using t test and P values as test of significance. Attempt was also 
made to link the difference in observations in both phases to the financial 
implications in provision of disposables for infection control programme. 
DATA COLLECTION AND ANALYSIS 
Collection of data: As per Performa attached. 
Analysis of data: Using statistical package SPSS software 
Conflict of interest: NIL 
Financial support: NIL 
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OBSERVATIONS AND RESULTS 
In Phase I trial, which was carried out between the months of August to 
October 2010, 177 case sheets were analysed (retrospectively the bateriologic 
profile for these months were analysed) in order to know about the pattern of 
organisms prevalent before the study. 
Overall estimates showed that CONS was the most common organism 
isolated followed by Proteus. Out of the 122 isolates gram +ve cocci were 58, 
gram -ve bacilli were 63, others 1. 
TABLE 1. BACTERIOLOGIC PROFILE IN PHASE I TRAIL 
ORGANISMS NO. OF ISOLATES 
CONS 39 
Proteus mirabilis 21 
Staphylococcus aureus 18 
Pseudomonas aeruginosa 14 
Klebsiella pneumonia 14 
Acinetobacter 6 
Escheriscia coli (ESBL) 5 
Candida spp 1 
Citrbacter spp 1 
Streptococcus spp 1 
Salmonella typhi 1 
Enterococci 1 
TOTAL 122 
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In the Phase II, trial samples were taken from different IMCU 
environments and from the patients, and were carried out between the months of 
December 2010 to February 2011. 
TABLE 2. TOTAL NO.OF PATIENT SAMPLES 
PHASE II TRIAL 
 
SAMPLES NO. OF SAMPLES 
Urine 47 
Tracheal aspirate 29 
Blood 17 
CVP catheter tip 02 
TOTAL 95 
 
Out of the 95 samples analysed, 93 organisms were isolated from 
patients’ samples. The most prevalent organism being Candida spp, followed by 
Psuedomonas aureginosa. 
TABLE 3. BACTERIOLOGIC PROFILE PATIENT SAMPLE 
PHASE II TRIAL 
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ORGANISM NO. OF ISOLATES 
Candida species 22 
Pseudomonas aeruginosa  15 
E.coli  11 
Non fermentative gram negative bacilli  9 
Enterococcus species 8 
Enterobacter species 8 
Klebsiella species 7 
Staphylococcus aureus 4 
Citrobacter species 4 
Coagulase negative Staphylococci 3 
Proteus species 2 
TOTAL 93 
 
 
Among these, out of the 47 urine samples, 59 organisms were isolated 
with Candida being the most commonly isolated organism. No growth was 
found in 11 samples.  
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TABLE 4. URINE SAMPLES - PHASE II TRIAL 
ORGANISMS NO. OF ISOLATES 
Candida species 18 
Escherichia coli 10 
Enterococcus species 8 
Klebsiella species 7 
NFGNB 6 
Enterobacter species 3 
Pseudomonas aeruginosa 2 
Citrobacter species 2 
Staphylococcus aureus 1 
Coagulase negative Staphylococci 1 
Proteus species 1 
TOTAL 59 
 
 
Out of the 29 tracheal aspirate samples, 33 organisms were isolated and 
were polymicrobial. Pseudomonas aeruginosa being the most common among 
them. No growth was noted in 7 samples.  
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TABLE 5. TRACHEAL ASPIRATE SAMPLES - PHASE II TRIAL 
ORGANISMS NO.OF ISOLATES 
Pseudomonas aeruginosa  13 
Enterbacter species 5 
Candida species  4 
Staphylococcus aureus 3 
Coagulase negative Staphylococci 2 
NFGNB 2 
Citrobacter species 2 
Proteus species 1 
E.coli 1 
TOTAL 33 
 
 
 
 
There was only one organism isolated from the blood culture samples & 
CVP catheter tip samples were negative. 97 environmental samples were 
analysed and 190 organisms were isolated. 
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TABLE 6. TOTAL NO.OF ENVIRONMENTAL SAMPLES 
PHASE II TRIAL 
 
SAMPLE TOTAL NO. OF  SAMPLES 
Bed 8 
Wall 7 
Floor 7 
Screen 6 
Ventilator 4 
Antiseptic  4 
Attender seating area 4 
Working staff hand  4 
Ventilator Stand 3 
Window 3 
IV stand 3 
Multi Monitor 3 
Cubicle Glass 3 
Bed spread  2 
Oxygen Mask 2 
Ambu bag 2 
Drug Tray 2 
X-ray lobby 2 
Emergency drug tray 2 
Computer 2 
Phone 2 
Doctor’s table 2 
Working table 2 
Pendent 2 
Cubicle Tray 1 
Ounce glass 1 
Mortar and pestle 1 
Laryngoscope 1 
Circuit box 1 
Feeding syringe 1 
Drug table 1 
Drug box 1 
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SAMPLE TOTAL NO. OF  SAMPLES 
Door knob 1 
Veranda cupboard 1 
Staff room 1 
Bathroom  1 
Veranda  1 
Veranda door  1 
Wall steel rim 1 
Cupboard  1 
TOTAL 97 
 
 
Coagulase negative Staphylococci was the most common organism isolated 
from the environment followed by Bacillus spp and Pseudomonas aureginosa. 
TABLE 7. BACTERIOLOGIC PROFILE ENVIRONMENTAL SAMPLES 
PHASE II TRIAL 
 
ORGANISM  NUMBER OF ISOLATES 
CONS  66 
Bacillus  29 
Pseudomonas 26 
NFGNB 23 
Micrococci  11 
Enterococci  10 
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ORGANISM  NUMBER OF ISOLATES 
Enterobacter  8 
Candida 6 
Staphylococcus aureus 5 
Klebsiella  4 
Citrobacter  1 
E.coli 1 
TOTAL 190 
 
WALL 
Total no of sample: 7 
Total no of isolates: 11 
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ENV SAMPLE-PHASE II
CONS
Bacillus 
Pseudomonas
NFGNB
Micrococci 
Enterococci 
Enterobacter 
Candida
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FLOOR 
Total no of sample: 7 
Total no of isolates: 18  
 
 
BED 
Total no of sample: 8 
Total no of isolates: 22 
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VENTILATOR SAMPLE 
Total no of samples: 4 
Total no of isolates: 6 
 
 
VENTILATOR  STAND 
Total no of samples: 3 
Total no of isolates: 8 
 
 
67 
 
SCREEN SAMPLE 
Total no of samples: 6 
Total no of isolates: 14 
 
BED SPREAD 
Total no of samples: 2 
Total no of isolates: 8 
 
ATTENDER SEATING AREA 
Total no of samples: 4 
Total no of isolates: 10 
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CUBICLE SEPARATING GLASS 
Total no of samples: 3 
Total no of isolates: 8 
 
WINDOWS 
Total no of samples: 3 
Total no of isolates: 5 
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In the Phase III, trial samples were taken from different IMCU environments 
and from the patients, and were carried out between the months of July 2011 to 
Sep 2011. 
TABLE 8. TOTAL NO.OF PATIENT SAMPLES - PHASE III TRIAL 
 
SAMPLES NO. OF SAMPLES 
Urine 51 
Tracheal aspirate 31 
Blood  12 
CVP cather tip 2 
TOTAL 96 
 
Out of the 96 samples analysed, 86 organisms were isolated from patients’ 
samples. The most prevalent organism being Candida spp, followed by 
Staphylococcus aureus. 
TABLE 9. BACTERIOLOGIC PROFILE PATIENT SAMPLES - PHASE III TRIAL 
 
ORGANISM NO. OF ISOLATES 
Candida species 19 
Staphylococcus aureus 14 
Acinetobacter species 9 
Corynebacterium species 8 
Pseudomonas aeruginosa 7 
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ORGANISM NO. OF ISOLATES 
Enterococcus species 7 
Klebsiella pneumoniae 6 
Klebsiella oxytoca 5 
Coagulase negative Staphylococci 5 
E.coli 4 
Non fermentative gram negative bacilli 2 
TOTAL 86 
 
PATIENT SAMPLE PHASE III TRIAL
Candida species
Staphylococcus aureus
Acinetobacter species
Corynebacterium species
Pseudomonas aeruginosa
Enterococcus species
 
Among these, out of the 51 urine samples 40 organisms were isolated 
with Candida being the most commonly isolated organism. No growth was 
found in 11 samples. 
      TABLE 10. URINE SAMPLES - PHASE III TRIAL 
 
ORGANISMS NO. OF ISOLATES 
Candida species 16 
Enterococcus species  5 
Klebsiella oxytoca 5 
Klebsiella pneumonia 4 
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ORGANISMS NO. OF ISOLATES 
Escherichia coli  4 
Acinetobacter species 3 
Pseudomonas aeruginosa 2 
Coagulase negative Staphylococci 1 
TOTAL 40 
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Out of  the 31 tracheal aspirate samples, 46 organisms were isolated and 
was polymicrobial. Staphylococcus aureus being the most common among 
them. No growth was noted in 7 samples.  
TABLE 11. TRACHEAL ASPIRATE SAMPLES - PHASE III TRIAL 
 
ORGANISMS NO.OF ISOLATES 
Staphylococcus aureus 14 
Corynebacterium species 8 
Acinetobacter species 6 
Pseudomonas aeruginosa 5 
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ORGANISMS NO.OF ISOLATES 
Coagulase negative Staphylococci 4 
Candida species 3 
Enterococci species 2 
Klebsiella species 2 
Non fermentative gram negative bacilli 2 
TOTAL 46 
 
 
 
There was no organism isolated from the blood culture samples & CVP catheter 
tip. 98 environmental samples were analysed and 178 organisms were isolated. 
 
    TABLE 12. TOTAL NO.OF ENVIRONMENTAL SAMPLES - PHASE III TRIAL 
 
SAMPLE NO OF SAMPLE 
AMBOBAG 2 
BED 10 
BED SPREAD 4 
BIOLOGICAL BINS 2 
COMPUTER 2 
CUBICLE SEPERATING GLASS 4 
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SAMPLE NO OF SAMPLE 
CURTAIN 4 
DRUG TABLE-2 2 
DRUG TRAY 4 
FLOOR 10 
FRIDGE INSIDE 2 
GENERAL TABLE 4 
IV STAND 3 
MILK GLASS 3 
MORTAR AND PESTLE 2 
MULTI MONITOR 4 
PENDENT 3 
SCREEN 8 
VENTILATOR OUTSIDE 2 
VENTILATOR INSIDE 2 
WALL 10 
WINDOW 4 
X RAY LOBBY 2 
ANTISEPTIC 2 
WORKING STAFF HAND 4 
TOTAL 98 
 
AMBOBAG
BED
BED SPREAD
BIOLOGICAL BINS
COMPUTER
CUBICLE SEPERATING GLASS
CURTAIN
DRUG TABLE-2
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TABLE 13. BACTERIOLOGIC PROFILE ENVIRONMENTAL 
SAMPLES - PHASE III TRIAL 
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ENV SAMPLES PHASE III
Staphylococci
NFGNB 
Bacillus 
Candida
Klebsiella pneumonia
Cat –ve bile esc –ve G+ve cocci
CONS
Klebsiella oxytoca
Pseudomonas 
Enterobacter
Entrococci
E.coli
 
WALL 
Total no of sample: 10 
Total no of isolates: 14 
ORGANISM NUMBER OF ISOLATES 
Staphylococci 71 
NFGNB  36 
Bacillus  26 
Candida 13 
Klebsiella pneumonia 10 
Cat –ve bile esculin –ve G+ve cocci 5 
CONS 5 
Klebsiella oxytoca 4 
Pseudomonas  3 
Enterobacter 2 
Entrococci 2 
E.coli 1 
TOTAL 178 
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FLOOR 
Total no of sample: 10 
Total no of isolates: 25  
 
BED 
Total no of sample: 10 
Total no of isolates: 12 
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BIOLOGIC BIN 
Total no of sample: 2 
Total no of isolate: 4 
 
DRUG TRAY 
Total no of sample: 4 
Total no of isolates: 6 
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FRIDGE INSIDE 
Total no of sample: 2 
Total no of isolates: 2 
 
GENERAL TABLE 
Total no of sample: 4 
Total no of isolates: 4 
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MORTAR AND PESTLE 
Total no of sample: 2 
Total no of isolates: 4 
 
PENDENT 
Total no of sample: 3 
Total no of isolates: 14 
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WINDOW 
Total no of sample: 8 
Total no of isolates: 6 
 
CUBICLE SEPARATING GLASS 
Total no of samples: 3 
Total no of isolates: 8 
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No of isolates
0
1
2
3
4
5
No of isolates
 
VENTILATOR SAMPLE (inside) 
Total no of samples: 2 
Total no of isolates: 5 
 
VENTILATOR  STAND (outside) 
Total no of samples: 2 
Total no of isolates: 5 
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COMPARISON OF PHASE II & III TRIAL 
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TABLE 14. MORTALITY RATES DURING PHASE II & PHASE III TRAIL 
 
PHASE NO. OF PATIENTS ADMITTED IN IMCU TOTAL NO. OF DEATHS % 
PHASE II Trial 198 76 38.38% 
PHASE III Trial 244 85 34.83% 
 
0 50 100 150 200 250
PHASE I trial
PHASE II trial
Total no. of deaths
No. of patients admitted in 
IMCU
 
On analyzing the data by T - test, the P values are as follows: 
PATIENT SAMPLES 
ORGANISM PHASE II PHASE III TOTAL  P-Value 
Candida species 22 19 41 0.5 
Pseudomonas 
aeruginosa 15 7 22 < 0.0001 
CONS 3 5 8 0.9 
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ORGANISM PHASE II PHASE III TOTAL  P-Value 
E.coli 11 4 15 < 0.001 
NFGNB 9 2 11 < 0.001 
 
ENVIRONMENTAL SAMPLES 
ORGANISM PHASE II PHASE III TOTAL P-Value 
CONS 66 5 71 < 0.0001 
Bacillus 36 23 59 0.01 
Enterococci 29 26 55 0.9 
Pseudomonas aeruginosa 26 3 29 < 0.0001 
Candida species 6 13 19 < 0.05 
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DISCUSSION 
Hospital acquired infection (HAI) are one of the major cause of mortality 
and morbidity of human lives. It also causes a huge economic burden. Many 
strategies and protocols are adopted by individual hospitals to curtail the impact 
of HAI. Our hospital, Rajiv Gandhi Government General Hospital caters around 
15000 out patients and 7000 in patients every day. It’s not surprising that the 
prevalence of infections is so high in wards and emergency rooms. So a study 
on the prevalence of infection in the intensive medical care unit and its 
sensitivity and resistance patterns and the adoption of various strategies to 
contain those infections will be a relevant issue. 
We conducted the study in three phases. Phase I is a retrospective part of 
this study. It was conducted in the period between 01-08-2010 to 31-10-2010. In 
this phase, we collected the data from the case sheets about the predominant 
pathogens isolated from the patient’s specimens and their prevalence, sensitivity 
and resistance patterns were assessed. Total number of patients admitted during 
that period and the duration of stay and mortality rates were calculated. 
Coagulase negative staphylococcus (31.97 %) was the predominant 
organism isolated during that period followed by Proteus mirabilis (17.21 %), 
Pseudomonas aeruginosa (11.48 %) and Klebsiella pneumonia (11.48 %). 
Mortality rate during that period stood by 76%. 
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Phase II study was conducted in the period of 01.12.2010 to 28.02.2011. 
In this period, extensive survey was undertaken. Specimens were collected from 
environmental sources such as bed, A/C vents, screens, patient’s attenders, 
health workers such as doctors, nurses and attending workers. Patients blood, 
urine samples, tracheal aspirate, CVP catheter tips, urinary catheter tips were 
collected. A total of 97 samples were taken and analysed. 190 isolates were 
obtained from environmental samples and 86 isolates were from patient’s side. 
Coagulase negative staphylococcus (34.74 %) was the predominant organism 
isolated from the environment of our IMCU. Bacillus (15.26 %) and 
Pseudomonas (13.68 %) are the next prevalent organisms. Candida species 
22.09 % was the most prevalent organism from patient’s isolates followed by 
Staphylococcus aureus (16.28 %). 
Out of 95 samples from patients, 47 (49.47 %) samples were of urine 
specimen. Out of 47 urine samples, organisms were isolated from 36 (76.6%) 
samples and 11 (23.4%) samples showed no growth of which Candida (50%) 
was the predominant organism identified followed by E.coli (27.78%). A total 
of 29 samples were taken from tracheal secretions. 22 samples showed positive 
results and no growth in remaining 7 samples. 33 isolates were obtained. 
Pseudomonas aeruginusa (39.39%) was the predominant organism. 
17 samples were of blood and all the samples except one were negative. The 
organism isolated was NFGNB. 2 CVP samples were obtained and their 
cultures showed negative results. 
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At the end of phase II study, preventive strategies were adopted. 
Preventive measures include education of health workers, protocols framed for 
change of linens, proper disposal of wastes, restricted entries, fumigation etc. 
These measures were followed for around 6 months.  
Phase III study was started on 01.07.2011 and continued till 30.09.2011. 
The collection procedure was repeated. 98 samples were taken from the 
environmental source which yielded 178 isolates. Here the predominant 
organism was Staphylococci (39.89%). The pattern has changed from coagulase 
negative staphylococci which was predominant in phase 2 to staphylococci. 
Pseudomonas which was prevalent in phase 2 (13.62%) has drastically reduced 
to 1.7%. 
51 urine samples were collected, 40 samples showed growth and 11 
samples were negative. Candida species (40%) were the predominant organism 
isolated. Both in Phase II & III, Candida were the most prevalent organism. 
This result has emphasized the specific strategies and protocols needed to 
contain this dreaded organism. This throws more light on methods needed to be 
adopted to eradicate this organism. 
31 samples were taken from tracheal secretions, of which 24 samples 
showed positive results and 7 were negative. Staphylococcus aureus (30.43%) 
was the predominant species. Here the Pseudomonas which was more prevalent 
in the phase 2 (39.39%) became less prevalent (10.87%). 12 blood samples 
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were collected and all the samples showed negative culture. 2 CVP catheter 
samples were taken and cultured. They showed no growth. 
Analysing the data statistically by the T- test, it is found that the reduction 
of Pseudomonas, E.coli and NFGNB from the patient sample after preventive 
measures is significant with P value < 0.001. Similarly the reduction of CONS, 
Pseudomonas from the environmental samples is significant. 
Thus, this study has demonstrated the prevalence of various organisms in 
various samples. The measures taken to contain the organisms even though was 
good but was not adequate enough to show the results. This emphasizes the 
need for more stringent measures and the specific protocols for eradicating 
particular and dormant organisms to be adopted. 
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CONCLUSION 
Our study was done in three phases to observe the pattern and prevalence 
of infection.  Our observation showed that the nosocomial infections are the 
major cause of mortality and morbidity. It imposes a huge economic burden on 
the hospitals and society. We observed the changing pattern of the prevalence of 
the organism over a period. This implies an important need to survey the wards 
periodically to tackle the nosocomial infections and to prevent the development 
of resistance. 
In our study, the prevalence of organisms was more in the samples from 
the environment. This emphasized the need for the importance of maintaining 
utmost sterilization. Even though the health workers are aware of nosocomial 
infections and its dreaded consequences, a strong protocol oriented approach is 
the need of the hour. Education of health workers and the common public will 
play a crucial role. 
Candida was predominant in the environmental samples in both phase 2 
and phase 3 study. This implies organism specific preventive measures should 
also be needed as species like Candida may be one of the major causes of 
mortality. 
The prevalence of organisms had not significantly reduced in phase 3 
study. This shows the need for effective protocol oriented approach and 
education for prevention. 
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To conclude, every hospital settings should draw their own protocol to 
defend nosocomial infections. Periodic surveillance and education of both 
health workers and public is strongly recommended. The importance of simple 
barrier precautions must be emphasized through repeated teaching of staff for 
their wholehearted compliance and good health practices. Prevention of 
nosocomial infections will reduce the mortality and morbidity of patients and 
help reduce the economic burden in the health sector. 
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LIMITATIONS  
This study has the following limitations:  
1. Preventive measures were not adequate and protocol oriented. There were 
also certain practical difficulties in following the preventive measures. 
2. Educating the population and health workers and their compliance in 
following it up could not be strictly monitored.  
3. Resistance pattern of the prevalent organisms was not looked for. 
4. Bacteriological load was not calculated. 
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ABBREVATIONS 
ARDS   Acute Respiratory Distress Syndrome 
ADEM  Acute Demyelinating Encephalomyelopathy 
AIDP  Acute Inflammatory Demyelinating Polyneuropathy 
 BSI   Bloodstream Infections  Pneumonias 
CIDP  Chronic Inflammatory Demyelinating Polyneuropathy 
CKD   Chronic Kidney Disease 
CNS   Central Nervous System 
CONS  Coagulase Negative Staphylococcus 
CVS   Cardio Vascular System 
E.Coli  Escherechia Coli 
FRI   Febrile Respiratory Illness 
GBS   Guillaine Barre Syndrome 
GI   Gastrointestinal Illness 
HAP   Hospital Associated Pneumonia 
HCAI  Health Care Associated Infections 
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HCW  Health Care Worker 
HEPA  High Efficiency Particulate Air 
HME   Heat Moister Exchanger 
HMEF  Heat Moister Exchanger with Filter 
HIV   Human Immuno-deficiency Virus 
ICU   Intensive Care Unit 
MRSA  Methicillin Resistant Staph Aureus 
NFGNB  Non-Fermentive  Gram Negative Bacilli 
NI   Nosocomial Infections 
RS   Respiratory System 
SARS  Severe Acute Respiratory Syndrome 
SHT   Sytemmic Hypertention 
S.aureus  Staphylococcus aureus 
TB   Tuberculosis 
UTI   Urinary Tract Infection 
VAP   Ventilator Associated Pneumonia 
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PROFORMA 
Name    : 
Age    : 
Sex    : 
Occupation   : 
Marital status  : 
Address   : 
IP.No    : 
Date of admission  : 
Date of transfer  : 
Referral from  : 
Date of sampling  : 
Admission diagnosis : 
BRIEF PATIENT HISTORY: 
Past or recent History of hospitalization : 
Treatment for medical/surgical illness  : 
Drug history     : 
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Allergy history     :  
Vaccination history    : 
Personal history     : 
History of alcohol and drug abuse  : 
High risk behavior     : 
PHYSICAL EXAMINATION 
GENERAL EXAMINATION 
                        Conscious level 
                        Orientation 
                        Febrile/Afebrile 
                        Lymphadenopathy 
Oral examination  : 
ENT examination  : 
Eye examination  : 
Skin examination  : 
Genital examination : 
VITAL SIGNS         
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  Pulse Rate  : 
  Blood Pressure      :    
  Respiratory rate : 
                   Temperature  : 
CARDIOVASCULAR SYSTEM : 
RESPIRATORY SYSTEM  : 
GASTROINTESTINAL SYSTEM: 
CENTRAL NERVOUS SYSTEM : 
                      GCS 
 INVESTIGATIONS 
CBC 
 TC 
 DC 
 PCV 
 HEMATOCRIT 
 ESR 
 PLATELETS 
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LFT 
 TOTAL BILIRUBIN 
 AST 
 ALT 
 SAP 
 TOTAL PROTEIN 
RFT                     
         BLOOD SUGAR 
 UREA 
 SERUM CREATININE 
 Na+ 
 K+ 
Chest X- ray : 
 
Blood Culture  : 
Sputum/tracheal culture : 
Urine culture  : 
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HIV    : 
Special interventions : 
             Ventilator   : 
             Dialysis   : 
            Blood product : 
TREATMENT 
FINAL OUTCOME: 
IMPRESSION: 
 
 
SAMPLE 
BLOOD URINE 
TRACHEAL 
SWAB 
SPECIAL 
SWABS 
I L I L I L I L 
 
ON 
ADMISSION 
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AFTER 
48 hrs 
        
  
 L - Load 
          I - Isolate  
INANIMATE OBJECTS 
S.NO SITE ISOLATE LOAD 
1.    
2.    
3.    
4.    
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MASTER CHART- ENVIRONMENTAL SAMPLES 
PHASE II TRIAL 
S.NO. SAMPLE DATE ISOLATES 
1. 2nd cubicle wall      16/12/10 No growth 
2. 3rd cubicle floor 16/12/10 NFGNB, Coagulase negative 
Staphylococci 
3. 4th cubicle bed 16/12/10 Pseudomonas, Coagulase 
negative Staphylococci, NFGNB 
4. 5th cubicle ventilator 16/12/10 Coagulase negative Staphylococci 
5. 6th cubicle screen 16/12/10 NFGNB 
6. 7th cubicle window 16/12/10 NFGNB 
7. Ambobag  16/12/10 No growth 
8. O2mask 16/12/10 No growth  
9. Rani staff hand swab 16/12/10 No growth 
10. Banu worker hand swab 16/12/10 No growth 
11. Lavanya staff hand swab 16/12/10 No growth 
12. Unknown hand swab 16/12/10 No growth 
13. Antiseptic 1 16/12/10 No growth 
14. 10th cubicle iv port 23/12/10 No growth 
15. 11th cubicle monitor 23/12/10 Coagulase negative 
Staphylococci, Pseudomonas, 
Enterobacter 
16. 12th cubicle tray 23/12/10 No growth  
17. 14th cubicle bed 23/12/10 Bacilli, Citrobacter 
18. 11th cubicle floor 23/12/10 NFGNB, Coagulase negative 
Staphylococci 
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S.NO. SAMPLE DATE ISOLATES 
19. 11th cubicle separating 
glass 
23/12/10 Coagulase negative 
Staphylococci, Enterococci, 
NFGNB, Bacillus 
20. 10th cubicle ventilator 23/12/10 Klebsiella, Pseudomonas 
21. Antiseptic 2 23/12/10 No growth 
22. 5th cubicle window curtain 30/12/10 Coagulase negative 
Staphylococci, Bacillus 
23. 6th cubicle ventilator stand 30/12/10 Klebsiella, Pseudomonas 
24. 7th cubicle wall 30/12/10 Bacillus, Pseudomonas, 
Coagulase negative Staphylococci 
25. 7th cubicle circuit box 30/12/10 Coagulase negative 
Staphylococci,Pseudomonas 
26. X-Ray lobby  30/12/10 Coagulase negative 
Staphylococci, 2 NFGNB, 
Pseudomonas, Micrococci 
27. Emergency drug tray 30/12/10 2 NFGNB, Pseudomonas 
28. Drug tray 30/12/10 Pseudomonas 
29. Laryngoscope  30/12/10 Pseudomonas 
30. 8th cubicle multimonitor 19/1/11 Coagulase negative Staphylococci 
31. 9th cubicle Bed spread 19/1/11 Pseudomonas, Enterococci, 
NFGNB, Bacillus, Candida 
32. 10th cubicle screen 19/1/11 Coagulase negative 
Staphylococci, Bacillus, 
Mirococci 
33. 11th cubicle screen 19/1/11 Pseudomonas, Enterobacter, 
Micrococci 
34. 12th cubicle wall 19/1/11 Coagulase negative Staphylococci 
35. 13th cubicle bed  19/1/11 NFGNB, Coagulase negative 
Staphylococci 
101 
 
S.NO. SAMPLE DATE ISOLATES 
36. 14th cubicle floor 19/1/11 Enterobacter, Coagulase negative 
Staphylococci, Bacillus 
37. Ambobag  19/1/11 Coagulase negative Staphylococci 
38. Antiseptic 3 19/1/11 No growth 
39. O2 mask 19/1/11 Coagulase negative Staphylococci 
40. Ounce glass 19/1/11 Pseudomonas, NFGNB, Candida 
 
41. Mortar and pestle 19/1/11 Coagulase negative 
Staphylococci,  Pseudomonas, 
Micrococci, Bacillus, Candida 
42. Feeding syringe 19/1/11 Coagulase negative 
Staphylococci, , 
Enterococci,Micrococci,Candida 
43. Computer 19/1/11 Coagulase negative 
Staphylococci, Enterococci 
44. Phone 19/1/11 Coagulase negative Staphylococci 
45. Ventilator inside 19/1/11 No growth 
46. Ventilator outside  19/1/11 No growth 
47. X-Ray lobby 19/1/11 Coagulase negative 
Staphylococci, Enterococci, 
Bacillus 
48. Computer 23/2/11 Coagulase negative 
Staphylococci, Bacillus 
49. 6th cubicle bed 23/2/11 Pseudomonas 
50. Drug tray-2 23/2/11 Coagulase negative 
Staphylococci, Micrococci 
51. Emergency tray 23/2/11 NFGNB, StaphylococcUS aureus 
52. 3rd Bed spread 23/2/11 Coagulase negative 
Staphylococci, Bacillus, 
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S.NO. SAMPLE DATE ISOLATES 
Enterococci 
53. 7th cubicle screen 23/2/11 Coagulase negative 
Staphylococci, Pseudomonas 
54. 6th cubicle ventilator stand 23/2/11 2 Coagulase negative 
Staphylococci, Enterobacter 
55. 2nd cubicle separating 
glass 
23/2/11 Pseudomonas, NFGNB, Bacillus 
56. Doctor’s table 23/2/11 Coagulase negative 
Staphylococci, Bacillus 
57. Working table  23/2/11 No growth 
58. Drug table 23/2/11 Coagulase negative Staphylococci 
59. 10th cubicle iv port 23/2/11 Coagulase negative Staphylococci 
60. Drug boxes 23/2/11 Coagulase negative 
Staphylococci, 
EnterococcI,Bacillus 
61. 10th cubicle wall 23/2/11 Coagulase negative Staphylococci 
62. Ventilator stand 23/2/11 Coagulase negative 
Staphylococci, Bacillus, Candida 
63. 10TH cubicle bed steel rim 23/2/11 Coagulase negative Staphylococci 
64. 11th cubicle bed 23/2/11 Coagulase negative Staphylococci 
65. 6th cubicle floor 23/2/11 Coagulase negative Staphylococci 
66. Antiseptics 23/2/11 No growth 
67. Attender seating area-1 27/2/11 Coagulase negative 
Staphylococci, Klebsiella, 
Micrococci, Bacillus 
68. Attender seating area-2 27/2/11 Coagulase negative Staphylococci 
69. Attender seating area-3 27/2/11 Staphylococcus aureus, 
Psuedomonas, Bacillus 
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S.NO. SAMPLE DATE ISOLATES 
70. Attender seating area-4 27/2/11 Enterococci, Bacillus 
71. 1st cubicle wall 27/2/11 Coagulase negative Staphylococci 
72. 1st cubicle H.D monitor 27/2/11 Coagulase negative 
Staphylococci, Enterococci 
73. 1st cubicle pendent 27/2/11 Coagulase negative 
Staphylococci, 
EnterococcI,Bacillus 
74. Working table 27/2/11 No growth 
75. Door knob 27/2/11 Coagulase negative 
Staphylococci,Pseudomonas 
76. Pendent  27/2/11 Coagulase negative 
Staphylococci, 
EnterococcI,Bacillus 
77. Cupboard 27/2/11 Coagulase negative 
Staphylococci,Staphylococcus 
aureus,Micrococci 
78. Skin cubicle wall 27/2/11 Pseudomonas,Enterobacter 
79. Skin cubicle floor 27/2/11 Coagulase negative 
Staphylococci, Bacillus, 
Micrococci 
80. Skin cubicle bed 27/2/11 2 Coagulase negative 
Staphylococci, Enterobacter, 
Bacilli 
81. Skin cubicle screen 27/2/11 Coagulase negative 
Staphylococci, Bacillus 
82. Veranda cupboard 27/2/11 Coagulase negative Staphylococci 
83. Phone 27/2/11 Coagulase negative 
Staphylococci,NFGNB 
84. Staff room  27/2/11 Coagulase negative 
Staphylococci, EnterococcI, 
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Pseudomonas,Bacillus 
85. Bathroom  27/2/11 Coagulase negative 
Staphylococci,2 NFGNB 
86. 1st cubicle bed 27/2/11 2 Coagulase negative 
Staphylococci, NFGNB 
87. 2nd cubicle floor 27/2/11 Enterobacter, Klebsiella, 
Coagulase negative 
Staphylococci, Bacillus 
88. 3rd cubicle wall 27/2/11  
89. 4th cubicle screen 27/2/11 Coagulase negative 
Staphylococci, NFGNB, 
Enterococci 
90. 5th cubicle separating 
glass 
27/2/11 Coagulase negative Staphylococci 
91. 6th cubicle window 27/2/11 Coagulase negative 
Staphylococci, Bacillus 
92. 7th cubicle iv port  27/2/11 No growth 
93. 8th cubicle bed  27/2/11 Pseudomonas, Coagulase 
negative Staphylococci, NFGNB, 
Bacilli 
94. Veranda 27/2/11 Staphylococc aureus, 
NFGNBPseudomonas,E.coli 
95. 1st cubicle floor 27/2/11  
96. Veranda door 27/2/11 Coagulase negative 
Staphylococci, Pseudomonas 
97. Doctor’s table 27/2/11 No growth 
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PHASE III TRIAL 
S.NO SAMPLE DATE ISOLATE 
1. 2nd cubicle bed 07/07/11 Staphylococci,candida 
2. 3rd cubicle wall 07/07/11 Staphylococci 
3. 4th cubicle bed 07/07/11 No growth 
4. 5th  cubicle floor 07/07/11 Staphylococci, NFGNB 
5. 6th cubicle screen 07/07/11 Staphylococci 
6. 7th cubicle window 07/07/11 Staphylococci 
7. Bed spread 07/07/11 NFGNB,Candida 
8. Antiseptic  07/07/11 No growth 
9. Computer  07/07/11 No growth 
10. General table 07/07/11 Staphylococci 
11. Iv stand 14/07/11 Staphylococci,  Bacillus 
12. Multimonitor 14/07/11 NFGNB,Staphylococci,Bacillus 
13. Biologic bin 14/07/11 CONS, Candida 
14. 10th cubicle window 14/07/11 Bacillus 
15. Working staff hand 14/07/11 No growth 
16. 12th cubicle bed 14/07/11 Bacillus 
17. 14th cubicle wall 14/07/11 NFGNB 
18. 11th cubicle floor 14/07/11 Staphylococci, Bacillus 
19. 11th cubicle screen 14/07/11 Staphylococci,NFGNB 
20. 10th cubicle bed spread 14/07/11 NFGNB,Candida 
21. Ambu bag 21/07/11 No growth 
22. 5th cubicle screen 21/07/11 Catalse-ve bile esculin –ve G+ve 
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cocci 
23. 6th cubicle bed 21/07/11 NFGNB 
24. 7th cubicle wall 21/07/11 Bacillus 
25. 7th cubicle floor 21/07/11 Bacillus 
26. X-Ray lobby  21/07/11 No growth 
27. Fridge  21/07/11 Bacillus 
28. Drug tray 21/07/11 Staphylococci 
29. Feeding syringe  21/07/11 No growth 
30. Mortar & pestle 21/07/11 NFGNB, Candida 
31. Ambu bag 03/08/11 No growth 
32. 4th cubicle bed  03/08/11 Klebsiella oxytoca 
33. 2nd  cubicle sep glass 03/08/11 3 Staphylococci,Candida 
34. Curtain  03/08/11 NFGNB,2Staphylococci, Enterococci 
35. Floor   03/08/11 Klebsiella oxytoca, 
Staphylococci,Candida 
36. Iv stand 03/08/11 2 Staphylococci, 1 Bacillus,Klebsiella 
oxytoca CONS, Candida 
37. Milk glass 03/08/11 NFGNB 
38. Wall  03/08/11 Staphylococci 
39. Bed spread 10/08/11 Klebsiella pneumoniae, Bacillus, 
NFGNB 
40. 5th cubicle sep glass 10/08/11 2 NFGNB 
41. Floor  10/08/11 Klebsiella pneumonia, 
,Staphylococci,Candida 
42. General table 10/08/11 Staphylococci 
43. Iv stand 10/08/11 NFGNB 
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44. Mortar & pestle 10/08/11 Klebsiella Pneumoniae, E.coli, 
45. Multimonitor  10/08/11 Klebsiella pneumoniae,2 
NFGNB,Staphylococci,Bacillus 
46. Pendant  10/08/11 3NFGNB,Staphylococci,Bacillus, 
Klebsiella pneumonia 
47. Screen  10/08/11 Klebsiella pneumoniae,Enterobacter 
48. Ventilator outside 10/08/11 Klebsiella pneumonia, 2NFGNB 
49. Wall  10/08/11 Staphylococci, ,NFGNB 
50. 8th cubicle bed  24/08/11 Staphylococci, candida 
51. 8th cubicle sep glass 24/08/11 Staphylococci 
52. Curtain  24/08/11 3 Staphylococci, Candida 
53. X ray lobby 24/08/11 Staphylococci 
54. Floor  24/08/11 Staphylococci,  Bacillus, 
Enterococci,Candida 
55. Multimonitor   24/08/11 Klebsiella pneumoniae, 
Bacillus,Staphylococci, CONS 
56. Pendant  24/08/11 2 Staphylococci,Bacillus,Klebsiella 
pneumonia 
57. Screen  24/08/11 Staphylococci 
58. Wall   24/08/11 Staphylococci, Bacillus 
59. Window  24/08/11 Staphylococci,2Bacillus 
60. 4th cubicle bed  05/09/11 Bacillus 
61. 6th cubicle sep glass 05/09/11 NFGNB,Staphylococci,CONS, 
Pseudomonas 
62. Curtain  05/09/11 NFGNB,2 Staphylococci 
63. Drug tray 05/09/11 Staphylococci 
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64. Floor  05/09/11 Staphylococci, , Catalase-ve bile 
esculin –ve G+ve cocci 
65. General table 05/09/11 Staphylococci, NFGNB 
66. Pendant  05/09/11 NFGNB,Staphylococci,Bacillus, 
Catalase-ve bile esculin –ve G+ve 
cocci 
67. Screen  05/09/11 Staphylococci, NFGNB,  CONS 
68. Wall  05/09/11 Staphylococci, Bacillus 
69. Window  05/09/11 Staphylococci 
70. Bed spread  14/09/11 NFGNB, Staphylococci,Bacillus, 
Candida 
71. Biologic bin 14/09/11 Staphylococci, Bacillus 
72. Computer  14/09/11 No growth 
73. Drug tray 14/09/11 NFGNB, 2Staphylococci 
74. Drug table 14/09/11 Staphylococci 
75. Fridge  14/09/11 Staphylococci 
76. Floor  14/09/11 Klebsiella pneumonia, 
2Staphylococci, NFGNB, Catalase-ve 
bile esculin –ve G+ve cocci 
77. Screen  14/09/11 2 Staphylococci, NFGNB 
78. Ventilator inside 14/09/11 NFGNB,Pseudomonas,Klebsiella 
oxytoca, Staphylococci 
79. Ventilator outside 14/09/11 2 Staphylococci, 
2NFGNB,Pseudomonas 
80. Wall  14/09/11 Staphylococci, Bacillus 
81. Bed 21/09/11 Catalase-ve bile esculin –ve G+ve 
cocci 
82. Skin cubicle bed 21/09/11 Bacillus 
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83. Wall  21/09/11 NFGNB 
84. Floor  21/09/11 Staphylococci 
85. Screen  21/09/11 Staphylococci 
86. Drug tray 21/09/11 Staphylococci 
87. Feeding syringe 21/09/11 No growth 
88. Drug table  21/09/11 Staphylococci 
89. General table 21/09/11 No growth 
90. Curtain  21/09/11 NFGNB,Staphylococci 
91. Bed  28/09/11 Staphylococci,candida 
92. Wall  28/09/11 Staphylococci 
93. Floor  28/09/11 Enterobacter, Bacilli 
94. Ventilator inside  28/09/11 NFGNB 
95. Antiseptic  28/09/11 No growth 
96. Workg staff hand 28/09/11 No growth 
97. Workg staff hand 28/09/11 No growth 
98. Workg staff hand 28/09/11 No growth 
 
 
S.No. Name Age Sex IP No. D.O.A. D.O.S. PR BP Temperature CVS RS CNS Diagnosis
1 Savithri 28yrs       F 99595 02-12-2010 14-12-2010 90 130/80 98.4F N N N GBS
2 Kumar 35yrs M 99640 07-12-2010 14-12-2010 86 120/80 98.4F N N N Hanging
3 Kousalya 40yrs F 103568 16-12-2010 22-12-2010 70 120/80 98.4F N N N Strangultion
4 Pushpalatha 22yrs F 104090 18-12-2010 22-12-2010 86 110/70 98.4F N N N AIDP
5 Poorani 48yrs F 102998 15-12-2010 22-12-2010 94 130/90 98.4F N N N AIDP
6 Senthil kumar 26yrs M 103224 15-12-2010 22-12-2010 80 120/80 98.4F N N N Young stroke/Rt hemiparesis
7 Karthika 22yrs F 104617 20-12-2010 22-12-2010 82 90/60 98.4F N N N Myasthenia Gravis
8 Kalavathy 22yrs F 104956 20-12-2010 22-12-2010 100 130/90 98.4F N N N Primary Pulm HTN
9 Amudha 51yr F 86757 20-12-2010 22-12-2010 88 120/80 98.4F N N N CIDP
10 Savithri 28yrs       F 99595 02-12-2010 22-12-2010 90 130/80 98.4F N N N GBS
11 Pushpalatha 22yrs F 104090 18-12-2010 23-12-2010 86 110/70 98.4F N N N AIDP
12 Poorani 48yrs F 102998 15-12-2010 23-12-2010 94 130/90 98.4F N N N AIDP
13 Savithri 28yrs       F 99595 02-12-2010 23-12-2010 90 130/80 98.4F N N N GBS
14 Senthil kumar 26yrs M 103224 15-12-2010 22-12-2010 80 120/80 98.4F N N N Young stroke/Rt hemiparesis
15 Karthika 22yrs F 104617 20-12-2010 22-12-2010 82 90/60 98.4F N N N Myasthenia Gravis
16 Kameshwaran 18yrs M 107204 28-12-2010 30-12-2010 88 120/80 98.4F N N N Hanging
17 Kumar 45yrs M 105549 25-12-2010 30-12-2010 80 130/90 98.4F N N N GBS
18 Shridevi 35yrs F 107521 30-12-2010 12-01-2011 92 90/60 98.4F N N N SHT/CAD/CKD
19 Lakshmi 20yrs F 1409 05-01-2011 12-01-2011 78 110/70 98.4F N N N Cortical Venous Thrombosis
20 Mohandas 50yrs M 1756 06-01-2012 12-01-2011 80 100/60 98.4F N N N Rheumatoid arthritis/ACD
22 Deepavathani 24yrs F 2928 10-01-2011 12-01-2011 100 120/80 98.4F N N N Hanging
23 Pushpalatha 22yrs F 104090 18-12-2010 12-01-2011 86 110/70 98.4F N N N AIDP
24 Ashokan 37yrs M 107045 31-12-2010 19-01-2011 100 110/80 98.4F N N N Pericardial effusion
25 Prabu 33yrs M 2897 10-01-2011 19-01-2011 78 140/70 98.4F N N N Cervical cord compression
26 Abdul rehman 50yrs M 3236 11-01-2011 19-01-2011 90 110/80 98.4F N N N CVA/Lt hemiplegia
27 Padmashree 25yrs F 3720 13-01-2011 19-01-2011 88 110/70 98.4F N N N Parachute mitral valve MS/AF
28 Pushpalatha 22yrs F 104090 18-12-2010 19-01-2011 86 110/70 98.4F N N N AIDP
29 Deepavathani 24yrs F 2928 10-01-2011 19-01-2011 100 120/80 98.4F N N N Hanging
30 Shridevi 35yrs F 107521 30-12-2010 19-01-2011 92 90/60 98.4F N N N SHT/CAD/CKD
31 Uma chandran 50yrs M 4655 18-01-2011 26-01-2011 84 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
32 Pushpalatha 22yrs F 104090 18-12-2010 26-01-2011 86 110/70 98.4F N N N AIDP
33 Deepavathani 24yrs F 2928 10-01-2011 26-01-2011 100 120/80 98.4F N N N Hanging
34 Chaterjee 48yrs M 5861 20-01-2011 27-01-2011 60 130/90 98.4F N N N SHT/Rec.CVA/Lt Hemiplegia
35 Arunachalam 40yrs M 6781 24-01-2011 27-01-2011 72 110/70 98.4F N N N AIDP
36 Govinda naidu 50yrs M 6875 25-01-2011 27-01-2011 86 130/80 98.4F N N N SHT/CKD
37 Prabu 33yrs M 2897 10-01-2011 27-01-2011 78 140/70 98.4F N N N Cervical cord compression
38 Uma chandran 50yrs M 4655 18-01-2011 27-01-2011 84 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
39 Pushpalatha 22yrs F 104090 18-12-2010 27-01-2011 86 110/70 98.4F N N N AIDP
40 Deepavathani 24yrs F 2928 10-01-2011 27-01-2011 100 120/80 98.4F N N N Hanging
41 Raja 27yrs M 7115 24-01-2011 30-01-2011 72 110/70 98.4F N N N GBS
42 Sarasu 30yrs F 8289 28-01-2011 30-01-2011 80 130/70 98.4F N N N Chr sen.motor radiculopathy
43 Pushpalatha 22yrs F 104090 18-12-2010 30-01-2011 86 110/70 98.4F N N N AIDP
44 Deepavathani 24yrs F 2928 10-01-2011 30-01-2011 100 120/80 98.4F N N N Hanging
45 Arunachalam 40yrs M 6781 24-01-2011 30-01-2011 72 110/70 98.4F N N N AIDP
46 Karthick 21yrs M 7690 26-01-2011 04-02-2011 92 110/70 98.4F N N N ADEM
47 Manikandan 27yrs M 10321 02-02-2011 04-02-2011 82 120/80 98.4F N N N Hanging
48 Munniyammal 38yrs M 10293 01-02-2011 04-02-2011 74 110/70 98.4F N N N AIDP
49 Kamala bai 40yrs M 10250 01-02-2011 04-02-2011 88 120/80 98.4F N N N SHT/CVA/Lt Hemiplegia
50 Pushpalatha 22yrs F 104090 18-12-2010 04-02-2011 86 110/70 98.4F N N N AIDP
51 Shridevi 35yrs F 107521 30-12-2010 04-02-2011 92 90/60 98.4F N N N SHT/CAD/CKD
52 Uma chandran 50yrs M 4655 18-01-2011 04-02-2011 84 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
53 Arunachalam 40yrs M 6781 24-01-2011 04-02-2011 72 110/70 98.4F N N N AIDP
54 Sarasu 30yrs F 8289 28-01-2011 04-02-2011 80 130/70 98.4F N N N Chr sen.motor radiculopathy
55 Anbuselvi 35yrs F 12893 03-02-2011 07-02-2011 86 100/70 98.4F N N N AIDP
56 Uma chandran 50yrs M 4655 18-01-2011 07-02-2011 84 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
57 Pushpalatha 22yrs F 104090 18-12-2010 07-02-2011 86 110/70 98.4F N N N AIDP
58 Raja 27yrs M 7115 24-01-2011 07-02-2011 72 110/70 98.4F N N N GBS
59 Sarasu 30yrs F 8289 28-01-2011 07-02-2011 80 130/70 98.4F N N N Chr sen.motor radiculopathy
60 Chokalingam 60yrs M 11523 07-02-2011 11-02-2011 88 150/100 98.4F N N N SHT/CVA/PCS
61 Sowmiya 15yrs F 10255 03-02-2011 11-02-2011 90 100/60 98.4F N N N Sezuire disorder
62 Sekar 38yrs M 11649 08-02-2011 11-02-2011 90 130/90 98.4F N N N Hanging
63 Maragatham 60yrs M 11607 07-02-2011 11-02-2011 90 120/90 98.4F N N N SCC Lung
64 Venkataswamy 48yrs M 11701 08-02-2011 11-02-2011 88 130/90 98.4F N N N AIDP
65 Uma chandran 50yrs M 4655 18-01-2011 11-02-2011 84 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
66 Pushpalatha 22yrs F 104090 18-12-2010 11-02-2011 86 110/70 98.4F N N N AIDP
67 Sarasu 30yrs F 8289 28-01-2011 11-02-2011 80 130/70 98.4F N N N Chr sen.motor radiculopathy
68 Sekar 38yrs M 11649 08-02-2011 16-02-2011 90 130/90 98.4F N N N Hanging
69 Pushpalatha 22yrs F 104090 18-12-2010 16-02-2011 86 110/70 98.4F N N N AIDP
70 Sarasu 30yrs F 8289 28-01-2011 16-02-2011 80 130/70 98.4F N N N Chr sen.motor radiculopathy
MASTER CHART PHASE II TRIAL - PATIENT SAMPLE
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HIV
Hb TC DC PL Sugar Urea Creatine Na K TB DB OT PT TP
9.2 4120 53/42/5 1.2 127 21 0.7 134 4 1 0.4 24 36 6 negative
12.6 5500 70/28/2 1.5 110 25 0.9 141 4.5 0.9 0.3 16 27 6.5 negative
11.5 6300 67/30/3 2.1 128 36 1 142 3.5 1 0.3 21 35 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.7 4340 72/27/1 2.5 65 18 0.5 144 3.5 0.8 0.3 28 35 6.8 negative
13.7 6700 76/22/2 1.37 116 26 0.8 134 4 0.9 0.4 28 29 6.9 negative
11.6 7800 71/26/3 2 76 22 0.8 135 3.5 0.8 0.2 25 30 6.9 negative
8 6000 70/26/4 2.14 76 40 1.2 141 4.5 0.8 0.2 30 35 5.8 negative
10.7 4700 60/39/1 3.96 126 22 0.6 136 3.6 0.9 0.3 20 22 6.4 negative
9.2 4120 53/42/5 1.2 127 21 0.7 134 4 1 0.4 24 36 6 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.7 4340 72/27/1 2.5 65 18 0.5 144 3.5 0.8 0.3 28 35 6.8 negative
9.2 4120 53/42/5 1.2 127 21 0.7 134 4 1 0.4 24 36 6 negative
13.7 6700 76/22/2 1.37 116 26 0.8 134 4 0.9 0.4 28 29 6.9 negative
11.6 7800 71/26/3 2 76 22 0.8 135 3.5 0.8 0.2 25 30 6.9 negative
13.4 4500 68/30/2 2.8 80 24 0.9 140 4 1 0.4 26 24 6.4 negative
13 6800 75/23/2 3.2 120 29 1 139 3.9 0.9 0.3 27 32 7 negative
10.3 9000 74/23/3 1.01 124 39 1.4 130 3 0.8 0.3 23 30 6.5 negative
10.2 6370 60/31/3 1.7 98 23 0.9 146 4 0.7 0.2 25 35 6.3 negative
11.3 4390 56/40/4 1.5 104 32 1.4 140 3.8 0.8 0.2 29 31 6.6 negative
11.4 6370 49/48/3 1.9 100 44 1.2 145 3.9 0.9 0.3 24 29 6.2 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.8 7450 68/31/1 2.1 101 28 1 138 4.7 0.9 0.2 21 27 6.6 negative
14 7100 60/34/1 1.48 110 40 1.1 133 3.5 0.9 0.3 27 31 6.6 negative
12.5 9400 75/24/1 1.42 92 24 1 135 3.5 1.2 0.3 24 33 5.9 negative
11.6 8390 73/26/1 1.7 110 40 1.2 140 4.7 1.2 0.3 30 44 6.5 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.4 6370 49/48/3 1.9 100 44 1.2 145 3.9 0.9 0.3 24 29 6.2 negative
10.3 9000 74/23/3 1.01 124 39 1.4 130 3.4 0.8 0.3 23 30 6.5 negative
13.6 7800 68/29/3 3.2 106 37 1 137 3.7 0.6 0.1 22 27 6.2 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.4 6370 49/48/3 1.9 100 44 1.2 145 3.9 0.9 0.3 24 29 6.2 negative
10.3 4100 62/34/4 2.1 119 50 1.1 145 4.8 0.8 0.2 20 31 6.2 negative
13 5500 65/32/3 1.2 104 28 1 143 4 1 0.3 26 29 6.6 negative
12.8 4700 74/24/1 2.1 80 30 0.9 138 4.1 0.9 0.3 24 29 6.1 negative
14 7100 60/34/1 1.48 110 40 1.1 133 3.5 0.9 0.3 27 31 6.6 negative
13.6 7800 68/29/3 3.2 106 37 1 137 3.7 0.6 0.1 22 27 6.2 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.4 6370 49/48/3 1.9 100 44 1.2 145 3.9 0.9 0.3 24 29 6.2 negative
13.5 9000 55/47/3 1.58 120 28 0.9 141 4.2 0.7 0.2 27 31 7.4 negative
9.8 6110 70/26/4 1.6 110 31 1 140 3.1 0.8 0.2 21 16 6.4 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
11.4 6370 49/48/3 1.9 100 44 1.2 145 3.9 0.9 0.3 24 29 6.2 negative
13 5500 65/32/3 1.2 104 28 1 143 4 1 0.3 26 29 6.6 negative
13.6 8050 67/31/2 2.5 126 26 0.9 143 3.8 1.5 0.5 23 33 7 negative
12.2 7390 66/32/2 2.1 105 47 1.2 144 3.4 0.8 0.2 40 48 6.2 negative
12 8000 68/30/2 1.9 110 30 0.6 146 3.8 0.9 0.4 28 30 6.5 negative
11.6 7600 75/24/1 1.75 118 48 1.2 139 4 0.9 0.3 24 35 6.9 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
10.3 9000 74/23/3 1.01 124 39 1.4 130 3.4 0.8 0.3 23 30 6.5 negative
13.6 7800 68/29/3 3.2 106 37 1 137 3.7 0.6 0.1 22 27 6.2 negative
13 5500 65/32/3 1.2 104 28 1 143 4 1 0.3 26 29 6.6 negative
9.8 6110 70/26/4 1.6 110 31 1 140 3.1 0.8 0.2 21 16 6.4 negative
11.8 5890 72/27/1 2 108 38 0.8 144 4.1 0.9 0.2 25 30 7.5 negative
13.6 7800 68/29/3 3.2 106 37 1 137 3.7 0.6 0.1 22 27 6.2 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
13.5 9000 55/47/3 1.58 120 28 0.9 141 4.2 0.7 0.2 27 31 7.4 negative
9.8 6110 70/26/4 1.6 110 31 1 140 3.1 0.8 0.2 21 16 6.4 negative
11.8 8000 70/28//2 2.5 125 40 1.5 148 3.7 1 0.3 34 44 6.5 negative
9.5 4100 76/20/4 1.27 120 24 1.2 137 3.8 0.9 0.3 59 68 6.4 negative
13.8 9840 60/36/4 2.5 110 28 1 140 3.3 1 0.3 28 35 6.9 negative
9 9000 60/38/2 2.13 100 28 0.8 140 4 0.8 0.2 34 54 6 negative
14 5647 71/27/2 1.9 118 27 0.8 137 4.1 0.9 0.3 27 36 6.6 negative
13.6 7800 68/29/3 3.2 106 37 1 137 3.7 0.6 0.1 22 27 6.2 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
9.8 6110 70/26/4 1.6 110 31 1 140 3.1 0.8 0.2 21 16 6.4 negative
13.8 9840 60/36/4 2.5 110 28 1 140 3.3 1 0.3 28 35 6.9 negative
10.8 7500 60/38/2 1.49 109 30 1 138 3.9 0.9 0.2 26 29 7 negative
9.8 6110 70/26/4 1.6 110 31 1 140 3.1 0.8 0.2 21 16 6.4 negative
CBC RFT LFT
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Intervention Blood Culture Urine Culture Tracheal Culture CVP Catheter 
Tip Culture
tracheostomy * Proteus mirabilis,E.coli Proteus vulgaris *
tracheostomy * * Pseudomonas,Enterobacter,Citrobacter,E.coli,Candida(large & small creamy) *
none * E.coli,Candida spp * *
tracheostomy * E.coli,Candida spp Citrobacter,Psuedomonas *
ET tube * Candida(large creamysmooth round white) NO GROWTH *
none * Enterococci spp * *
none * NO GROWTH * *
none * NO GROWTH Insufficient sample *
none NFGNB * * *
tracheostomy * * Coagulase negative Staphylococcus *
tracheostomy NO GROWTH * * *
ET tube NO GROWTH * * *
tracheostomy NO GROWTH * * *
none NO GROWTH Enterococci spp * *
none NO GROWTH * * *
none NO GROWTH * * *
none NO GROWTH NFGNB * *
none NO GROWTH Enterobacter spp,Candida spp * *
none * Enterobacter spp,Candida spp * *
none * Klebsiella,NFGNB * *
intubation NO GROWTH INSUFFICIENT SAMPLE *
tracheostomy * Enterococci spp INSUFFICIENT SAMPLE *
none NO GROWTH * * *
none NO GROWTH * * *
intubation NO GROWTH NO GROWTH Pseudomonas *
none * Enterococci spp,Candida spp * *
tracheostomy NO GROWTH Candida spp Pseudomonas *
intubation NO GROWTH Candida spp 2Pseudomonas,Enterobacter *
none NO GROWTH E.coli,Candida spp * *
tracheostomy * NFGNB NO GROWTH *
tracheostomy * * Enterobacter,Candida *
intubation * * Enterobacter,Staphylococcus aureus *
none * NO GROWTH * *
intubation * Candida spp,Enterococci spp * *
none * Candida spp * *
none * Enterococci spp * *
tracheostomy * Candida spp * *
tracheostomy * E.coli,Candida spp * *
intubation * Klebsiella spp * *
none * Pseudomonas aureginosa * *
none * Coagulase negative Staphylococcus * *
tracheostomy * Klebsiella oxytoca * *
intubation * Candida spp * *
intubation * * Coagulase negative Staphylococcus *
none * Staphylococcus aureus * *
none * NO GROWTH * *
none * NO GROWTH * *
none * NO GROWTH * *
tracheostomy * E.coli NFGNB *
none * * * NO GROWTH
tracheostomy * Enterococci spp Pseudomonas *
intubation * Klebsiella spp Staphylococcus aureus *
none * Klebsiella oxytoca * *
none * E.coli * *
tracheostomy * * Pseudomonas,NFGNB,Candida NO GROWTH
tracheostomy * Enterococci spp Pseudomonas *
none NO GROWTH * * *
none NO GROWTH * * *
intubation * NO GROWTH Staphylococcus aureus *
intubation * NO GROWTH Pseudomonas *
intubation * Candida spp Pseudomonas *
intubation * Pseudomonas aureginosa NO GROWTH *
intubation * Klebsiella spp Pseudomonas *
tracheostomy * NFGNB,Citrobacter spp Pseudomonas,Enterobacter *
tracheostomy * E.coli,Candida spp NO GROWTH *
none * E.coli,Candida spp * *
intubation * NO GROWTH * *
tracheostomy * NFGNB,Citrobacter spp * *
none * Klebsiella oxytoca,E.coli * *
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S.No. Name Age Sex IP No. D.O.A. D.O.S. PR BP Temperature CVS Rs CS Diagnosis
1 Diwakar 33yrs M 56586 04-07-2011 07-07-2011 86 120/80 98.4F N N N Hanging
2 Jegadeesan 35yrs M 50281 01-07-2011 07-07-2011 88 110/70 98.4F N N N GBS
3 Chinnamani 25yrs M 51902 02-07-2011 07-07-2011 72 130/80 98.4F N N N Young stroke/Rt hemiparesis
4 Venkatesan 50yrs M 56570 05-07-2011 07-07-2011 86 120/70 98.4F N N N ADEM
5 Jayamalini 40yrs F 53584 04-07-2011 07-07-2011 90 120/80 98.4F N N N Hypoxic Ischemic Encephalopathy
6 Soundaraj 15yrs M 54598 04-07-2011 07-07-2011 82 120/80 98.4F N N N AIDP
7 Kumar 38yrs M 56521 05-07-2011 14-07-2011 80 90/60 98.4F N N N CIDP
8 Suresh 29yrs M 52551 02-07-2011 14-07-2011 96 120/80 98.4F N N N AIDP
9 Devi 18yrs F 58722 10-07-2011 14-07-2011 80 130/80 98.4F N N N Myasthenia Gravis
10 Sekar 45yrs M 58572 10-07-2011 14-07-2011 88 120/80 98.4F N N N GBS
11 Karthick 21yrs M 58890 11-07-2011 14-07-2011 90 100/70 98.4F N N N Hanging
12 Venkatesan 19yrs M 58907 12-07-2011 14-07-2011 86 110/80 98.4F N N N SHT/CVA/PCS
13 Thambiah 60yrs M 69860 07-08-2011 10-08-2011 82 100/60 98.4F N N N Hanging
14 Rajkumar 23yrs M 65985 01-08-2011 10-08-2011 72 130/90 98.4F N N N CVA/Lt hemiplegia
15 Manimala 26yrs F 68157 04-08-2011 10-08-2011 88 90/60 98.4F N N N Hypoxic Ischemic Encephalopathy
16 Damodharan 38yrs M 69980 07-08-2011 10-08-2011 82 130/90 98.4F N N N Hanging
17 Prathab 16yrs M 69866 07-08-2011 10-08-2011 88 120/80 98.4F N N N GBS
18 Subramani 60yrs M 71228 08-08-2011 10-08-2011 72 110/70 98.4F N N N GBS
19 Gyansingh 30yrs M 74880 22-08-2011 24-08-2011 78 90/60 98.4F N N N Hanging
20 Murali 26yrs M 70652 08-08-2011 24-08-2011 80 120/80 98.4F N N N Paraplegia
21 Gandhi 50yrs M 76023 18-08-2011 24-08-2011 88 100/70 98.4F N N N GBS
22 Yusuf 25yrs M 71252 08-08-2011 24-08-2011 84 100/60 98.4F N N N AIDP
23 Veeraraghavan 60yrs M 76145 18-08-2011 24-08-2011 90 110/80 98.4F N N N CVA/Rt hemiplegia
24 Kumar 35yrs M 72912 10-08-2011 24-08-2011 78 140/70 98.4F N N N GBS
25 Deepalakshmi 28yrs F 74510 17-08-2011 24-08-2011 80 110/80 98.4F N N N Myasthenia Gravis
26 Subramani 60yrs M 71228 08-08-2011 24-08-2011 72 110/70 98.4F N N N GBS
27 Velu 40yrs M 79372 01-09-2011 05-09-2011 86 110/70 98.4F N N N Hanging
28 Kameshwari 30yrs F 77591 25-08-2011 05-09-2011 88 120/80 98.4F N N N Pemphigus
29 Latha 47yrs F 77586 25-08-2011 05-09-2011 92 90/60 98.4F N N N AIDP
30 Murugan 33yrs M 79453 02-09-2011 05-09-2011 84 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
31 Vijayalakshmi 20yrs F 79467 02-09-2011 05-09-2011 86 140/90 98.4F N N N CVA/Recurrent CVA
32 Malliga 48yrs F 78570 01-09-2011 05-09-2011 86 130/80 98.4F N N N SHT/CKD
33 Kameshwari 30yrs F 77591 25-08-2011 14-09-2011 88 120/80 98.4F N N N Pemphigus
34 Vijayalakshmi 20yrs F 79467 02-09-2011 14-09-2011 86 140/90 98.4F N N N CVA/Recurrent CVA
35 Malliga 48yrs F 78570 01-09-2011 14-09-2011 86 130/80 98.4F N N N SHT/CKD
36 Indrani 25yrs F 83467 12-09-2011 14-09-2011 90 120/60 98.4F N N N Hanging
37 Rajendran 50yrs M 79989 05-09-2011 14-09-2011 78 140/70 98.4F N N N Myasthenia Gravis
38 Chandra 53yrs F 81556 10-09-2011 14-09-2011 88 130/80 98.4F N N N SHT/Lt trans sinus thrombosis
39 Regima 31yrs F 87665 07-09-2011 14-09-2011 84 110/70 98.4F N N N ADEM
40 Mariappan 45yrs M 89854 18-09-2011 21-09-2011 100 120/80 98.4F N N N Hanging
41 Jeyakumar 37yrs M 89732 18-09-2011 21-09-2011 72 110/70 98.4F N N N GBS
42 Rajendran 50yrs M 79989 05-09-2011 21-09-2011 78 140/70 98.4F N N N Myasthenia Gravis
43 Subramani 60yrs M 71228 08-08-2011 21-09-2011 72 110/70 98.4F N N N GBS
44 Deepalakshmi 28yrs F 74510 17-08-2011 21-09-2011 80 110/80 98.4F N N N Myasthenia Gravis
45 Regima 31yrs F 87665 07-09-2011 21-09-2011 84 110/70 98.4F N N N ADEM
46 Malliga 48yrs F 78570 01-09-2011 21-09-2011 86 130/80 98.4F N N N SHT/CKD
47 Vasu 28yrs M 95366 25-09-2011 28-09-2011 80 120/80 98.4F N N N Hanging
48 Prabhu 42yrs M 96008 25-09-2011 28-09-2011 88 110/70 98.4F N N N AIDP
49 Suganya 17yrs F 94556 24-09-2011 28-09-2011 92 120/80 98.4F N N N GBS
50 Subramani 60yrs M 71228 08-08-2011 28-09-2011 72 110/70 98.4F N N N GBS
51 Deepalakshmi 28yrs F 74510 17-08-2011 28-09-2011 80 110/80 98.4F N N N Myasthenia Gravis
52 Radha 23yrs F 94578 24-09-2011 28-09-2011 84 110/70 98.4F N N N Hanging
53 Jeyakumar 37yrs M 89732 18-09-2011 28-09-2011 72 110/70 98.4F N N N GBS
MASTER CHART PHASE III TRAIL - PATIENT SAMPLE
113
Hb TC DC PL Sugar Urea Creatine Na K TB DB OT PT TP
11.8 6560 72/27/2 1.38 132 26 0.8 145 3.9 0.9 0.3 28 40 6.5
10.8 7500 70/28/2 2.5 109 30 1 143 3.8 0.8 0.3 20 32 6.2
12.4 6832 67/30/3 2.5 121 28 1 140 4 1 0.4 25 38 6.4
11.8 7700 60/38/2 2 113 34 1.2 135 3.5 0.7 0.2 28 40 5.4
10.7 4675 72/27/1 2.7 120 20 0.6 145 3.9 0.9 0.4 25 39 7
12.9 6800 76/22/2 2 92 19 0.9 146 4.2 1 0.4 21 22 5.8
12.6 7900 71/26/3 1.2 78 26 1 145 3.5 0.7 0.2 24 36 6.2
9.2 6200 70/26/4 1.01 65 40 1 134 4.5 0.8 0.2 29 31 5.8
10.9 4800 60/39/1 4 128 30 0.7 138 3.8 0.9 0.3 24 28 6.2
9.8 4500 53/42/5 1.6 128 26 0.8 143 3.5 0.9 0.4 28 36 6.2
11.8 7800 60/38/2 1.47 108 32 1 140 3.5 0.8 0.3 28 32 7
11.9 4545 72/27/1 2.6 72 20 0.7 120 4 1 0.4 24 36 6.9
10.2 4500 53/42/5 1.4 128 22 0.8 135 3 1 0.4 24 29 6.2
12.8 4700 76/22/2 1.38 127 28 0.9 138 3.5 0.8 0.2 27 32 5.8
12.6 7700 71/26/3 2.2 32 26 0.9 138 3.5 0.9 0.2 28 32 6.4
12.4 4700 68/30/2 2.8 90 28 1 143 4.3 0.7 0.2 23 30 6.8
12.8 6700 75/23/2 3.2 128 44 1.2 146 3.5 1 0.4 28 32 7
10.3 9000 74/23/3 1.01 124 39 1.4 130 3 0.8 0.3 23 40 7
11.2 4395 60/31/3 1.5 100 44 1.2 145 3.9 0.8 0.2 32 40 6.7
12.4 4390 56/40/4 1.2 109 38 0.7 138 4 0.8 0.2 31 43 7
11.8 6570 49/48/3 1.7 120 42 1.1 140 3.6 0.9 0.2 25 38 6.2
10.8 7600 60/38/2 1.48 110 32 1 144 3.7 0.9 0.2 28 32 6.8
10.8 7500 68/31/1 3.2 122 32 1.1 140 4.7 1.2 0.3 27 44 6.6
13.4 7200 60/34/1 1.46 120 44 1.2 138 3.6 0.9 0.3 28 33 6.4
13 9600 75/24/1 1.32 94 30 1 135 3.5 1.2 0.3 27 42 7
10.3 9000 74/23/3 1.01 124 39 1.4 130 3 0.8 0.3 23 40 7
9.8 7800 60/38/2 1.48 112 35 1.2 137 3.5 0.8 0.2 32 42 6.8
11.2 6550 49/48/3 1.8 119 43 0.9 147 3.8 0.8 0.2 28 30 6.2
10.2 9300 74/23/3 3.3 124 40 1.2 134 3.6 0.9 0.3 29 34 6.6
13.8 7900 68/29/3 3.2 121 27 1 140 4.2 0.6 0.1 20 32 6.1
11.2 7600 60/38/2 1.48 107 31 1.2 135 3.8 1 0.3 28 36 6.2
11.8 7800 74/24/1 2.5 90 38 1 135 4 0.9 0.3 30 28 7
11.2 6550 49/48/3 1.8 119 43 0.9 147 3.8 0.8 0.2 28 30 6.2
11.2 7600 60/38/2 1.48 107 31 1.2 135 3.8 1 0.3 28 36 6.2
11.8 7800 74/24/1 2.5 90 38 1 135 4 0.9 0.3 30 28 7
9.5 8600 75/23/2 3.6 105 34 1 140 4.5 1 0.2 24 36 6
14.2 5600 60/34/1 1.48 120 44 1.2 132 4 1 0.3 28 30 6.5
13.8 8100 68/29/3 3.5 111 38 0.7 145 3.8 0.7 0.2 24 28 5.8
11.8 7600 60/38/2 1.6 103 32 1 141 4.2 1 0.3 28 30 6.5
11.6 6970 49/48/3 1.8 90 40 1 145 3.8 0.8 0.2 26 30 7.2
12.5 6230 55/47/3 1.45 125 26 0.7 137 3.1 0.6 0.1 28 16 6.2
14.2 5600 60/34/1 1.48 120 44 1.2 132 4 1 0.3 28 30 6.5
10.3 9000 74/23/3 1.01 124 39 1.4 130 3 0.8 0.3 23 40 7
13 9600 75/24/1 1.32 94 30 1 135 3.5 1.2 0.3 27 42 7
11.8 7600 60/38/2 1.6 103 32 1 141 4.2 1 0.3 28 30 6.5
11.8 7800 74/24/1 2.5 90 38 1 135 4 0.9 0.3 30 28 7
12 6110 66/32/2 2.5 110 39 1.1 130 4.2 1 0.3 22 35 6.8
13 7500 68/30/2 2 109 31 0.7 137 3.6 0.7 0.2 22 27 6.2
10.6 7800 75/24/1 3 124 28 0.6 138 4.2 0.9 0.2 28 36 6.5
10.3 9000 74/23/3 1.01 124 39 1.4 130 3 0.8 0.3 23 40 7
13 9600 75/24/1 1.32 94 30 1 135 3.5 1.2 0.3 27 42 7
13.2 7600 68/29/3 3.2 95 38 0.9 140 3.2 0.9 0.2 21 27 6.6
12.5 6230 55/47/3 1.45 125 26 0.7 137 3.1 0.6 0.1 28 16 6.2
CBC RFT LFT
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HIV Intervention Blood Culture Urine Culture Tracheal Culture CVP Catheter Tip 
Culture
negative none * NO GROWTH * *
negative intubation *
Candida spp Staphylococcus aureus,Corynebacterium spp
*
negative none * E.coli * *
negative intubation * Candida spp INSUFFICIENT SAMPLE *
negative none * Klebsiella oxytoca * *
negative none NO GROWTH NO GROWTH * *
negative tracheostomy * * Staphylococcus aures,NFGNB *
negative tracheostomy * * Staphylococcus aureus *
negative none * NO GROWTH NO GROWTH *
negative none * Candida spp * *
negative none * Klebsiella pneumoniae * *
negative none NO GROWTH Klebsiella oxytoca * *
negative none * Candida spp * *
negative none *
Pseudomonas aeruginosa,Candida spp *
*
negative intubation *
Klebsiella oxytoca Acinetobacter spp,Pseudomonas 
aeruginosa,Corynebacterium spp *
negative none * Coagulase negative Staphylococci * *
negative intubation *
NO GROWTH Acinetobacter spp,Staphylococcus 
aures,Corynebacterium spp *
negative intubation NO GROWTH
Candida spp Acinetobacter spp,Pseudomonas aeruginosa
*
negative none * NO GROWTH * *
negative none * Klebsiella pneumoniae,Candida spp * *
negative intubation *
NO GROWTH Staphylococcus aureus,Corynebacterium spp
*
negative tracheostomy *
Acinetobacter spp Staphylococcus aureus,Corynebacterium spp
*
negative intubation * Candida spp Staphylococcus aureus *
negative none NO GROWTH Enterococcus spp,Candida spp * *
negative tracheostomy * NO GROWTH Staphylococcus aureus *
negative tracheostomy *
Enterococcus spp,Candida spp Staphylococcus aureus,Corynebacterium 
spp,Pseudomnas aeruginosa
*
negative none * NO GROWTH * *
negative none * Enterococcus spp * *
negative tracheostomy NO GROWTH
Esherichia coli,Candida spp Acinetobacter spp,Pseudomonas 
aeruginosa,Corynebacterium spp NO GROWTH
negative intubation * NO GROWTH NO GROWTH *
negative none * Klebsiella oxytoca * *
negative intubation * * Acinetobacter spp *
negative none * Enterococcus spp * *
negative none NO GROWTH Enterococcus spp,Candida spp * *
negative tracheostomy * Klebsiella pneumoniae * *
negative none *
* Coagulase negative 
Staphylococci,Enterococcuc spp,Candida 
spp *
negative tracheostomy NO GROWTH
NO GROWTH Klebsiella pneumoniae,Staphylococcus 
aureus *
negative intubation *
Candida spp Acinetobacter spp,Pseudomonas 
aeruginosa,Corynebacterium spp,Candida 
spp *
negative tracheostomy * NO GROWTH NFGNB *
negative intubation NO GROWTH * Staphylococcus aureus *
negative intubation * Pseudomonas aeruginosa NO GROWTH *
negative tracheostomy NO GROWTH Klebsiella oxytoca * *
negative tracheostomy * Acinetobacter spp Staphylococcus aureus NO GROWTH
negative tracheostomy *
Candida spp Coagulase negative 
Staphylococci,Staphylococcus aureus *
negative tracheostomy NO GROWTH Esherichia coli NO GROWTH *
negative tracheostomy *
* Coagulase negative Staphylococci,Candida 
spp *
negative intubation * * INSUFFICIENT SAMPLE *
negative intubation * * Enterococcus spp *
negative none NO GROWTH Candida spp * *
negative tracheostomy * Esherichia coli Staphylococcus aureus *
negative tracheostomy * Acinetobacter spp Klebsiella pneumoniae *
negative intubation * Candida spp NO GROWTH *
negative intubation NO GROWTH Klebsiella pneumoniae Coagulase negative Staphylococci *
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OUR INTENSIVE MEDICAL CARE UNIT 
 
 
PREVENTIVE MEASURES INTRODUCED 
1. Fumigation  
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2. Daily Mopping of the floors, Cleaning of walls and windows 
 
 
 
3. Cleaning of wash basins and bathrooms 
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4. Proper hand washing 
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5. Changing of bed linens, screens 
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6. Maintaining the cleanliness around the patient 
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7. Proper waste disposal 
 
 
 
8. Use of aprons, caps, masks 
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9. Attenders education 
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10. Limiting the entry of attenders 
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11. Collection of swabs 
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PATIENT CONSENT FORM 
STUDY DETAIL 
“STUDY OF BACTERIOLOGIC PROFILE IN CRITICAL CARE SETTINGS AND 
EFFECTS OF PREVENTIVE MEASURES” 
STUDY CENTRE  :             Rajiv Gandhi Government General Hospital, Chennai. 
 
PATIENTS NAME  : 
PATIENTS AGE   : 
IDENTIFICATION NUMBER        : 
   Patient may check (     ) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to ask 
question and all my questions and doubts have been answered to my complete satisfaction.   
I understand that my participation in the study is voluntary and that I am free to withdraw at any time without 
giving reason, without my legal rights being affected.        
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical committee and 
the regulatory authorities will not need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not to restrict the use of any data or results that 
arise from this study.          
        
I agree to take part in the above study and to comply with the instructions given during the study and faithfully 
cooperate with the study team and to immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.       
I hereby consent to participate in this study.               
I hereby give permission to undergo complete clinical examination and diagnostic tests including hematological, 
biochemical, radiological tests.          
 
Signature/thumb impression:    
Patients Name and Address:                   Place     Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place     Date      
 
 
